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Resumo 
 
O sistema imunitário engloba milhões de células que formam uma estrutura dinâmica e em 
comunicação, com o objetivo de defender o hospedeiro contra a entrada de agentes patogénicos e outras 
ameaças, como o aparecimento de células cancerígenas. No ser humano, a resposta imunitária envolve 
diversos tipos de células e, para cada tipo, estados celulares diferentes, interagindo entre si, de forma a 
manter e a proteger a função e integridade do organismo.  
Ao longo da vida o sistema imunitário vigia continuamente o organismo, através de um equilíbrio que 
envolve células imunitárias efectoras e reguladoras. No entanto, com o envelhecimento, ocorre um 
declínio gradual deste sistema, definido como imunosenescência. Esta deterioração leva a alterações nas 
proporções de diferentes tipos de células imunitárias no organismo e nas suas competências, o que, por 
sua vez, contribui para o aumento da prevalência de cancro, bem como para a propensão para um estado 
de inflamação crónica de baixo grau, implicado noutras doenças relacionadas com o envelhecimento, 
tais como as doenças neurodegenerativas. De facto, a idade é o principal fator de risco para o 
desenvolvimento da doença de Alzheimer e da doença de Parkinson. A sobreposição temporal entre o 
envelhecimento e a neurodegeneração tem alimentado um debate contínuo sobre se todos nós somos 
suscetíveis a desenvolver uma doença neurodegenerativa se vivermos tempo suficiente. Esta hipótese é 
sustentada pelo facto de o cérebro envelhecido apresentar várias lesões que não estão presentes no 
cérebro de pessoas mais jovens e de essas lesões se assemelharem a uma versão de grau inferior às 
encontradas nas doenças neurodegenerativas mais comuns. Muitos dos mecanismos implicados nas 
doenças neurodegenerativas são paralelos às mudanças que ocorrem com o envelhecimento e a maioria 
dos cérebros de idosos apresenta alterações específicas que podem ser ligadas a um certo nível de 
neurodegeneração, tal como a agregação de placas proteicas tóxicas e a neuro-inflamação.  
A neuro-inflamação consiste numa desregulação do sistema imunitário, associada à ativação e hiper-
reactividade da microglia, o principal tipo de células imunitárias no sistema nervoso central. Os 
astrócitos são outro tipo de célula não-neuronal presente no sistema nervoso central, que participa na 
constituição da barreira hematoencefálica e providencia suporte aos neurónios, entre outras funções. 
Estas células também se tornam excessivamente reativas com o envelhecimento. A neuro-inflamação é, 
assim, uma potencial causa das alterações funcionais que ocorrem durante o envelhecimento normal e 
patológico, tendo um efeito tremendo no aumento da suscetibilidade às doenças neurodegenerativas. A 
exacerbação, com a idade, de processos inflamatórios no sistema nervoso central leva à perda da 
homeostase e, consequentemente, à disfunção ou morte de células neuronais, tal como observado na 
doença de Alzheimer e na doença de Parkinson. Contudo, uma minoria de pessoas ultrapassa a idade 
dos 80 anos sem mostrar sinais de debilitação cognitiva. Estas pessoas são a prova da existência de 
mecanismos compensatórios, que lhes permitem envelhecer saudavelmente e manter uma cognição 
normal.  
O envelhecimento é também um dos principais factores de risco do cancro. O cancro da mama é uma 
doença particularmente associada às mulheres mais velhas, raramente ocorrendo antes dos 30 anos de 
idade, e com maior prevalência acima dos 60 anos de idade. Todos os anos, mais de 1,5 milhões de 
mulheres são diagnosticadas com cancro da mama, tornando-o o cancro mais comum, bem como o 
segundo mais mortal, nas mulheres, a nível mundial. 
As terapias tradicionais do cancro da mama incluem quimioterapia e radioterapia. Contudo, o tratamento 
desta doença continua a ser um desafio devido à sua natureza heterogénea. Aliás, existem vários subtipos 
de cancro da mama, sendo o mais agressivo o cancro da mama triplo-negativo. Ainda não existem 
medicamentos e/ou terapias especificamente direcionadas ao tratamento deste tipo de cancro, o que 
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enfatiza a necessidade de explorar terapias alternativas, tal como a imunoterapia, tendo em conta que a 
importância do sistema imunitário no cancro da mama é inequívoca.  
O microambiente tumoral é composto por matriz extracelular e células infiltradas na massa tumoral. 
Estas incluem uma proporção elevada de células tanto do o sistema imunitário inato como do adaptativo. 
As células imunitárias no microambiente tumoral foram já descritas como sendo determinantes na 
iniciação, progressão e metastização do cancro. Apesar da existência de subtipos diferentes de cancro 
da mama, e da variabilidade interindividual de doentes, estudos recentes, focados no microambiente 
tumoral, demonstraram a existência de padrões de infiltração de células imunitárias correlacionados com 
prognóstico (negativo ou favorável) em doentes com cancro da mama. Por exemplo, existe uma 
associação entre a infiltração de linfócitos, nomeadamente células T CD8+, e prognóstico favorável da 
doente, dado que estas células possuem funções citotóxicas capazes de eliminar células tumorais. Desta 
forma, as células T, no microambiente tumoral, já foram extensivamente estudadas e relacionadas como 
um componente fundamental do mesmo, devido a ensaios clínicos recentes que demonstraram a 
capacidade de controlar a progressão do cancro nalguns doentes ao manipular estas células.  
Contudo, as células mieloides, que englobam um conjunto de células do sistema imunitário inato, 
permanecem menos estudadas do que as células T, apesar de constituírem uma proporção significativa 
das células imunitárias infiltradas no microambiente tumoral. Dessas células, destacam-se os 
macrófagos, que podem atingir proporções superiores a 50% da própria massa tumoral na mama. Estas 
células apresentam polarizações diferentes conforme os estímulos do microambiente, podendo adotar 
um fenótipo que inibe o crescimento do tumor (anti-tumoral) ou que o favorece (pro-tumoral). A 
presença de macrófagos pró-tumorais no microambiente tumoral tem vindo a ser descrita como um 
indicador de prognóstico negativo no cancro, incluindo no cancro da mama. Por outro lado, os 
macrófagos anti-tumorais têm a capacidade de induzir a regressão dos tumores, pelo que, geralmente, 
encontram-se associados a um prognóstico favorável no cancro da mama. A existência de macrófagos 
com funções antagónicas torna-os num tópico de investigação ativo na área do cancro da mama, com o 
objectivo de desenvolver novas imunoterapias, direcionadas à diminuição dos números de macrófagos 
pro-tumorais, ou à re-polarização dos mesmos em macrófagos anti-tumorais.  
Assim, é importante caracterizar a heterogeneidade celular do sistema imunitário, possibilitando o 
conhecimento dos processos biológicos fundamentais que ocorrem no envelhecimento saudável e na 
doença. Para tal, é possível utilizar single-cell RNA sequencing, uma abordagem que utiliza tecnologias 
de sequenciação do transcritoma de uma única célula, permitindo medir a distribuição dos níveis de 
expressão de cada gene numa população de células individuais e melhor entender os padrões de 
expressão génica em tecidos complexos, como o cérebro e o microambiente tumoral. 
O desenvolvimento de protocolos de single-cell RNA sequencing foi motivado pela necessidade de 
estudar condições em que apenas uma pequena quantidade de material se encontrava disponível, tal 
como o desenvolvimento embrionário. Contudo, o aperfeiçoamento de protocolos e das plataformas de 
sequenciação permitiu um aumento no número de células utilizadas nestes ensaios, podendo chegar às 
centenas de milhares de células por estudo. Esta evolução contínua tem vindo a melhorar radicalmente 
a dissecção da heterogeneidade de populações celulares, particularmente na estimação da infiltração de 
células imunitárias em tumores sólidos, e na área das neurociências, permitindo caracterizar a grande 
diversidade de células neuronais e não-neuronais em várias regiões do sistema nervoso central. 
Este trabalho consistiu em duas partes, ambas envolvendo a análise de dados públicos de single-cell 
RNA sequencing. Na primeira parte, focámo-nos em desenvolver uma pipeline de análise 
computacional, de forma a estudar as abundâncias relativas de células neuronais e não-neuronais no 
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cérebro, e como a abundância destas populações se correlaciona com o envelhecimento e patologias 
neurológicas.  
Com esta análise demonstrámos que, para alguns tipos específicos de tecido cerebral, ocorre um 
decréscimo na proporção de neurónios com a idade, concomitante com um aumento na proporção de 
astrócitos. Esta alteração de proporções é acentuada na doença de Alzheimer e na doença de Parkinson, 
nas quais os tecidos afetados pela neurodegeneração demonstram uma proporção relativa inferior de 
neurónios, bem como uma proporção relativa superior de astrócitos, quando comparados com tecidos 
cerebrais sem doença.  
Também demonstrámos que o sistema nervoso central não é um local totalmente imuno-privilegiado 
pois conseguimos estimar as abundâncias absolutas de diferentes tipos de células imunitárias no cérebro. 
Aliás, esta análise revelou que, as células T CD4+ de memória são as células imunitárias que se infiltram 
em maior quantidade no cérebro, existindo uma variabilidade elevada entre indivíduos.  
A segunda parte deste trabalho teve como objectivo avaliar a diversidade celular e a assinatura molecular 
de macrófagos infiltrados no microambiente tumoral no cancro da mama, bem como caracterizar os 
padrões de infiltração de células imunitárias na massa tumoral e o modo como estes se encontram 
associados com a idade e o prognóstico.  
Com esta análise, identificámos grupos de macrófagos infiltrados na massa tumoral com fenótipos 
diferentes, tais como macrófagos com funções pró-inflamatórias anti-tumorais e macrófagos 
alternativamente ativados, ou seja, com funções anti-inflamatórias pró-tumorais. Por outro lado, 
descobrimos ainda um grupo de macrófagos transcricionalmente ativos, que não se assemelham a 
nenhuma das polarizações previamente descritas, tratando-se, possivelmente, de um novo estado por 
descrever.  
Verificámos ainda a ocorrência de um aumento significativo com a idade na proporção relativa de 
macrófagos pró-tumorais no microambiente tumoral do cancro da mama. Estes macrófagos têm a 
capacidade de suprimir a resposta anti-tumoral das células T CD8+ citotóxicas. Ao comparar grupos de 
tumores com uma proporção relativa elevada/baixa de macrófagos pró-tumorais, e grupos de tumores 
com uma proporção relativa baixa/elevada de células T CD8+, verificámos que a infiltração de 
macrófagos pró-tumorais parece estar associada com o processo biológico de transição epitelial-
mesenquimal, o qual está envolvido no potencial metastático dos tumores malignos. Em contraste, a 
infiltração de células T CD8+ encontra-se associada ao reconhecimento do tumor e à consequente 
elicitação de uma resposta imunitária ativa.  
Palavras-chave: single-cell RNA sequencing, envelhecimento, imunosenescência 
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Abstract  
 
Throughout the course of life, the immune system keeps surveilling the organism for foreign pathogens 
and cancerous cells. However, with ageing there is a gradual decline of the immune system fitness, 
which is defined as immunosenescence. This deterioration leads to alterations in the proportions of 
different immune cell types in the organism and in their capabilities. Moreover, it contributes to the 
increased prevalence of cancer as well as a propensity of a chronic low-grade inflammatory state 
implicated in other age-related diseases, such as neurodegenerative ones.  
The immune system comprises a multitude of different cell types and states. It is important to assess this 
cell heterogeneity in order to understand fundamental biological processes in healthy ageing and disease. 
One way to do this is through single-cell RNA sequencing, an approach that uses sequencing 
technologies to profile the transcriptome of a single cell, thereby allowing to measure the distribution of 
expression levels for each gene across a population of individual cells, and to better understand gene 
expression patterns in complex heterogeneous tissues, such as the brain and the tumour 
microenvironment.  
Using publicly available single-cell RNA sequencing datasets, the first part of this work was focused on 
developing a computational analysis pipeline to study the relative abundance of neuronal and non-
neuronal cells in the brain and how they correlate with ageing and neurological health. 
We found that, for some brain tissues, there is a decrease in the proportion of neurons with ageing, 
concomitant with an increase in the proportion of astrocytes. This shift in proportions is accentuated in 
Alzheimer’s disease and Parkinson’s disease, in which specific brain tissues affected by 
neurodegeneration show a relatively lower proportion of neurons and a relatively higher proportion of 
astrocytes, when compared with controls. We also demonstrated that the central nervous system in not 
totally an immune-privileged tissue without infiltration of blood-leucocytes, by estimating absolute 
abundances of different immune cell types in the brain. This revealed that resting CD4+ memory T cells 
present the highest proportion of brain-infiltrating immune cells, with a relatively high level of 
variability between individuals. 
In the second part of this work, our goal was to evaluate the cellular diversity and molecular signature 
of breast tumour-associated macrophages, and to understand how the intra-tumoural diversity and 
functionality of infiltrating immune cell types was associated with age and prognosis.  
By implementing single-cell RNA sequencing data analysis tools, we were able to discern groups of 
tumour-infiltrating macrophages with different phenotypes, such as the classically activated polarization 
(anti-tumour) macrophages and the alternatively activated polarization (pro-tumour) ones. On the other 
hand, we found a group of transcriptionally activate macrophages that do not resemble any of the 
previously described polarizations, possibly being a new unstudied state. We also found that there is a 
significant increase in the relative proportion of breast tumour-infiltrating pro-tumour macrophages with 
ageing. These macrophages are known to suppress CD8+ cytotoxic T cell-mediated anti-tumour immune 
responses. By comparing groups of breast tumour bulk RNA-sequencing samples with a high/low 
proportion of pro-tumour macrophages, and a low/high proportion of CD8+ T cells, we found that 
infiltration of pro-tumour macrophages is associated with the cancer metastasis hallmark (epithelial-
mesenchymal transition).  In contrast the tumours with higher infiltration of CD8+T cells, were 
associated with the recognition of the breast tumour as non-self and the consequent elicitation of an 
active immune response. 
Keywords: single-cell RNA sequencing, ageing, immunosenescence 
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1. The Immune System 
 
The immune system consists of millions of cells that form a dynamic communicating structure, with the 
goal of defending the host against infecting pathogens and other agents, such as malignant transformed 
cells. The immune response in human health and disease involves a multitude of different cell types and 
states, interacting amongst each other and with non-immune cells, to maintain and protect tissue function 
and integrity. The distinct elicited immune responses, along with the immune cells that are part of this 
complex network, can be classified into two major components: the innate immune system and the 
adaptive immune system (Goldman and Prabhakar 1996). 
 
1.1. Innate Immune system 
 
The innate immune response is an immediate and non-specific defence mechanism. Besides including 
anatomical barriers that avoid the entrance of infectious agents in the organism, this response is 
dependent on the recruitment of natural killer and myeloid cells. Natural killer (NK) cells are effector 
lymphocytes with cytotoxicity and cytokine-producing effector functions, directed at killing infected 
host cells and tumour cells, limiting their spread (Vivier et al. 2008). Myeloid cells can be phagocytic 
(neutrophils, monocytes, dendritic cells and macrophages) or inflammatory mediator-releasing cells 
(basophils, mast cells, and eosinophils) (Delves and Roitt 2000). 
Monocytes are blood-circulating phagocytes that can develop into macrophages or dendritic cells after 
migrating into tissues (Karlmark, Tacke and Dunay 2012).  
Dendritic cells (DC) are potent antigen-presenting cells (APCs), acting in tissues that are in contact with 
the external environment, linking the innate and the adaptive arms of the immune system (Mellman 
2013).  Myeloid-derived DCs are usually considered a distinct cell type from plasmacytoid dendritic 
cells (pDC), given that they may not descend from the myeloid lineage (Reizis 2019). 
Macrophages are highly adherent and motile phagocytes that patrol tissues for potential pathogens. They 
also produce large amounts of pro-inflammatory cytokines and chemokines, and are able to recruit 
lymphocytes through antigen-presentation, assisting the initiation of the adaptive immune response 
(Goldman and Prabhakar 1996).   
Monocytes and macrophages from different tissues, together with their precursors, constitute the 
mononuclear phagocyte system, in which monocytes replace resident macrophages in all major organs, 
by adopting specific gene expression profiles, which translate into distinct functions. Kupffer cells in 
the liver and alveolar macrophages in the lung are two examples of specialized monocyte-derived 
macrophages (Hume, Irvine and Pridans 2019). 
Neutrophils, basophils and eosinophils are granulocytic cells, i.e., they contain cytoplasmic granules 
filled with antimicrobial products, inflammation mediators, and cytotoxic proteins, respectively. While 
neutrophils engulf and digest pathogens, basophils and eosinophils degranulate the content of their 
granules in response to parasitic infections and allergies. Mast cells have similar functional 
characteristics as basophils. However, unlike the latter, they reside in tissue instead of the bloodstream 
(Goldman and Prabhakar 1996).   
In the central nervous system (CNS), the major resident myeloid cells are microglia. Microglia survey 
the microenvironment and release trophic factors which are important for neuronal cell survival. Their 
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phagocytosis capability is also important in synaptic homeostasis and clearance of cellular debris 
resulting from injury. Although functionally similar to macrophages, microglia originate from the yolk 
sac and populate the CNS prior to its vasculogenesis (Nayak, Roth and McGavern 2014). Microglia, 
together with oligodendrocytes and astrocytes, are the major components of glia, i.e., the main non-
neuronal cells of the CNS, that are key in maintaining homeostasis and neuronal function. Representing 
the larger fraction of glia in the brain, astrocytes are responsible for the maintenance of ion homeostasis 
and the blood-brain barrier (BBB), production of neurotrophic factors, participation in the formation, 
maturation and elimination of synapses, and uptake of neurotransmitters. Furthermore, astrocytes play 
a role in local immune regulation, by releasing inflammatory mediators that activate and amplify the 
initial innate immune response, and by altering BBB permeability, allowing the entrance of peripheral 
blood immune cells in the brain parenchyma (Vasile, Dossi and Rouach 2017; Farina, Aloisi and Meinl 
2007). 
 
1.2. Adaptive immune system 
 
The adaptive immune response, also known as the acquired immune response, is mediated by specialized 
cells, capable of targeting pathogens more accurately than the innate system, and of a long-term 
response, enabled by the generation of immunological memory. This leads to a more efficient immune 
response when the pathogen is reencountered (Delves and Roitt 2000). These specialized cells are 
lymphocytes, namely antigen-specific B and T cells.  
Activated B cells (short-lived plasma cells) secrete neutralizing immunoglobins that bind to and lead to 
the elimination of pathogens. Like macrophages and dendritic cells, they are also APCs. Some B cells 
become pathogen-experienced memory B cells, which are important in eliciting an enhanced immune 
response in the case of re-infection (Goldman and and Prabhakar 1996; Kurosaki, Kometani and Ise 
2015). 
T cells can be categorized into three distinct subsets: effector T cells, regulatory T cells and memory T 
cells. Effector T cells actively respond to stimuli and can be further divided into helper T cells and 
cytotoxic T cells. Helper T cells express the CD4 molecule and regulate the immune response, by 
producing cytokines that stimulate phagocytic cells, aid B cell proliferation and differentiation, and 
assist other effector T cells in cell-mediated immunity. Cytotoxic T cells express the CD8 molecule and 
directly kill infected or altered cells, through the production of cytolytic enzymes. Regulatory T cells, 
also known as suppressor T cells, express CD4 and are involved in preventing immune overreaction, by 
supressing T and B cell activity (Cano and Lopera 2013). Memory T cells can be either CD4+ or CD8+, 
and represent long-lived populations of T cells that can rapidly differentiate into effector T cells, when 
re-encountering pathogens to which they were previously exposed (Omilusik and Goldrath 2017). 
In summary, the innate response is a nonspecific response that is not altered by the number of times the 
same pathogen is encountered. The adaptive response is a highly specific and long-lasting response that 
is enhanced when the pathogen is re-encountered. Both systems are connected in a complex net of 
relationships that allows them to work together to neutralize potential threats to the organism.  Thus, the 
failure in any component of the immune system may lead to a deficient immunosurveillance state. 
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2. Neurodegenerative diseases 
 
For the first time in history, we are rapidly approaching a shift in the world’s population age 
distributions. It is expected that, by the year 2030, people older than 60 years will have already 
outnumbered children under the age of 10, and, by 2050, they will also outnumber children and young 
adults between 10 to 24 years of age (United Nations 2017).  
Although the desired increase in life expectancy is a product of the success of medical advancements, 
public health and socio-economical improvements, global ageing is expected to lead to an accelerated 
increase in the prevalence of neurodegenerative disorders, such as Alzheimer’s disease (AD) and 
Parkinson’s disease (PD) (Erkkinen, Kim and Geschwind 2017). Both these diseases are sources of 
growing morbidity and mortality rates, particularly in the elderly.  
AD and PD present different clinical symptomatology and progression, albeit there are overlapping 
features in their pathological processes, such as defects in proteostasis and immune regulation, 
concomitant with a common inflammatory mechanism, implicated in the chronic progression of most 
neurodegenerative diseases (Gao and Hong 2008).  
 
2.1. Alzheimer’s disease 
 
Late-onset AD is the most common cause of dementia in the world. It is characterised by progressive 
short-term memory loss, followed by language, visuospatial and executive function impairment. Patients 
in later stages may also display motor dysfunction. The disorder eventually culminates in death, with 
patients living, on average, 8 to 10 years, after diagnosis (Schachter and Davis 2000).  
The pathology of AD is associated with the accumulation of neurofibrillary tangles and deposition of 
neuritic plaques in the brain (Figure 2.1B) (Zheng and Koo 2006). Neuritic plaques consist of insoluble 
deposits of β-amyloid peptide (Aβ), a fragment of the larger amyloid precursor protein (APP). Currently, 
it is still unclear whether neuritic plaques are a cause or a consequence of AD. Previous studies report 
contrasting hypotheses, for example, either stating that dysfunction in the metabolism of APP, with 
subsequent increase in the insoluble Aβ, is responsible for AD (Schachter and Davis 2000), or that 
plaques exist in both the cognitive impaired elderly and elderly which show no loss of cognitive ability 
(Makin 2018).   
Neurofibrillary tangles are intracellular accumulations of modified tau protein, secondary to Aβ 
deposition. In the healthy brain, tau proteins are microtubule stabilizers. However, in AD brain, tau 
proteins are hyperphosphorylated, leading to their self-polymerization and to the formation of tangles 
(Kolarova et al. 2012).  
In spite of their unclear role in the pathology of AD, it is known that neurofibrillary tangles and neuritic 
plaques are neurotoxic and can lead to neuron degeneration, either by directly disrupting signalling and 
obstructing cell function, or by indirectly causing inflammation and oxidative stress (Farias et al. 2011; 
Yankner, Duffy and Kirschner 1990; Huang, Zhang and Chen 2016). 
The distribution pattern of neurofibrillary tangles and neuronal alterations in a subject’s brain is used to 
verify the stage of AD progression (Braak and Braak 1991). In Braak stages I and II, neuronal alterations 
are confined to the transentorhinal region of the brain (Figure 2.1A). Stages III and IV occur when there 
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is involvement of the transentorhinal region and the hippocampus, and V and VI when there is extensive 
neocortical degeneration (Dossi, Vasile and Rouach 2018).  
 
 
Figure 2.1: Disease progression in Alzheimer's disease. A - Distribution pattern of neurofibrillary tangles and abnormal 
neurites; B - Immunohistochemical staining of intracellular neurofibrillary tangles (brown, indicated by arrows) and 
extracellular neuritic plaques (pink, indicated with a circle). Scale bar 50 µm.  Adapted from Vies 2016. 
 
Currently, there is no treatment to stop AD progression, with existing pharmaceutical therapies, e.g. 
acetylcholinesterase inhibitors and memantine, only providing modest cognitive and functional benefits 
(Pierce, Bullain and Kawas 2017). 
 
2.2. Parkinson’s disease  
 
PD is the second most common neurodegenerative disease. PD mainly affects the motor system and is 
characterised by slow movement and an impaired ability to move the body swiftly on command. 
Manifestations such as tremors and muscle stiffness are also common in PD. Dementia can also be 
present in later stages (Costantini, D’Angelo and Reale 2018). The median age of onset is 60 years, with 
patients living, on average, 15 years after diagnosis (Erkkinen, Kim and Geschwind 2017). However, 
the age of the patient seems to be responsible for the progression of clinical symptoms, rather than the 
age of disease onset (Hindle 2010).  
Although the cause of PD is still unknown, motor symptoms are attributed to the loss of dopaminergic 
neurons in the substantia nigra pars compacta, resulting in a decrease of dopamine levels in the brain 
(Costantini, D’Angelo and Reale 2018). Another characteristic feature of PD is the presence of Lewy 
bodies, resulting from accumulation of α-synuclein and ubiquitin aggregates in the neuronal cytoplasm. 
α-synuclein is also present in neuronal processes, as well as in astrocytes and oligodendrocytes (Shults 
2006). 
Braak staging in PD is performed according to the degree and localization of Lewy body accumulation, 
neurodegeneration and consequent clinical symptomology. In stage I, pathological changes occur only 
in the dorsal motor nucleus and olfactory bulb. Stage II involves Lewy body formation in the pons and 
medulla. In stage 3 and 4, patients exhibit clinical motor symptoms, and stages 5 and 6 involve 
degeneration of the neocortex, leading to cognitive impairment and dementia (Figure 2.2) (Hindle 2010).  
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Figure 2.2: Progression of Parkinson's disease as proposed by Braak et al. From Visanji et al. 2013. 
 
There is no cure for Parkinson's disease. Current therapies symptoms are mainly symptomatic and 
include pharmacologic therapies that target the motor features of PD, by improving dopamine signalling. 
Anticholinergics are also effective for patients with a tremor-predominant phenotype, as well as deep 
brain stimulation with microelectrodes, which can alleviate motor fluctuation (Erkkinen, Kim and 
Geschwind 2017). 
 
2.3. Overlap between ageing and neurodegeneration 
 
Age is the primary risk factor for AD and PD (Yankner, Lu and Loerch 2008). The overlap between 
ageing and neurodegeneration has fuelled a continuous debate as to whether we are all liable to develop 
a neurodegenerative disorder if we live long enough. This hypothesis is sustained by the fact that the 
aged brain presents several lesions that are not present in the brains of younger people, and that these 
lesions resemble a lower grade version of the ones found in neurodegenerative disease. In fact, many of 
the mechanisms implicated in neurodegenerative disease are parallel to the changes that occur with 
ageing, and the majority of aged brains show characteristic alterations, such as plaque accumulation,  
that can be linked to a certain level of neurodegeneration (Yankner, Lu and Loerch 2008; Hindle 2010). 
Moreover, the machinery behind protein synthesis, folding, disaggregation and degradation can be 
compromised with ageing, having profound consequences for disease presentation and progression 
(Wyss-Coray 2016). 
Nevertheless, a minority of the population surpasses the age of 80 without showing any signs of 
cognitive impairment, and are designated as the “Super Agers” (Gefen et al. 2019). Super Agers 
highlight the possible existence of compensatory mechanisms, which are lost in normal agers, and that 
enable them to age healthily and maintain normal cognition. 
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2.3.1. Neuro-inflammageing  
 
Inflammageing is a chronic low-grade inflammation state associated with ageing. In the CNS, this 
inflammatory phenotype is named neuro-inflammageing and is present in most neurodegenerative 
diseases, including AD and PD (Wyss-Coray 2016). Neuro-inflammageing consists of a dysregulation 
of the immune system, related to the activation and hyperreactivity of microglia, and the subsequent 
production of pro-inflammatory cytokines (Wyss-Coray 2016). There’s also an increase in the number 
and density of microglia in the aged brain (Figure 2.3), which may be due to compensatory mechanisms, 
related with their reduced capacity of phagocytosis, after being engorged with debris of degenerating 
myelin (Gefen et al. 2019).  
With ageing, astrocytes also become reactive, showing increased expression of glial fibrillary acidic 
protein (GFAP) (Palmer and Ousman 2018; Hol and Pekny 2015). Pro-inflammatory activated microglia 
and reactive astrocytes are also present in AD and PD pathogenesis. This phenomenon occurs together 
with neuronal loss and increase in microglia proliferation (Figure 2.3A-2.3F) (Wyss-Coray 2016; Qian 
and Flood 2008; Joe et al. 2018; Clayton, Van Enoo and Ikezu 2017). 
 
 
Figure 2.3: Staining of activated microglia in the white matter of the inferior frontal gyrus (A, B, C) and in corpus callosum 
(D, E, F). SuperAger – individual over the age of 85 whose memory test scores were at a level equal to or superior than scores 
of 50-to-65-year-olds. Normal Old - cognitively normal elderly over the age of 70; Young – cognitively normal young adult 
under the age of 24. From Gefen et al. 2019. 
 
Activated microglia may also be involved in the generation of neuritic plaques seen in AD, either by 
secretion of Aβ or through the release of agents such as iron, which aggregates soluble Aβ fibrils (Wyss-
Coray 2016). The progressive accumulation of iron is characteristic of ageing, and is exacerbated in 
selective brain regions in neurodegenerative disease, including the substantia nigra, leading to 
neurotoxicity (Ward et al. 2014; Hindle 2010). 
Altered astrocytes contribute to a dysfunctional BBB with increased permeability (Yamazaki and 
Kanekiyo 2017), allowing activated peripheral blood immune cells, such as monocytes, to reach the 
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CNS. Monocytes differentiate into pro-inflammatory M1 macrophages, which produce cytokines and 
ROS, contributing to neuronal damage and death (Constantini, D’Angelo and Reale 2018). 
In summary, neuro-inflammageing is a potential trigger of the functional changes that occur during 
normal and pathological ageing, and has a powerful effect on enhanced susceptibility to 
neurodegenerative diseases. Enhanced neuroinflammatory processes lead to loss of homeostasis in the 
brain environment, and, consequently, result in the death or dysfunction of neurons as seen in 
neurodegenerative disease.  
 
3. Breast Cancer 
 
Ageing is a major risk factor for the development of solid cancers (Zinger, Cho and Ben-Yehuda 2017; 
WHO 2011), with over 75% of all invasive cancers occurring in susceptible populations aged 55 years 
or older (Benz 2008). Moreover, the number of new cancer cases per year is expected to rise to 23.6 
million by 2030 (National Cancer Institute 2019). 
Breast cancer is also a disease primarily of older women, rarely occurring before age 30 and with the 
highest rates over 60 years of age (Fundo IMM Laço 2019). Over 1.5 million women (25% of all women 
with cancer) are diagnosed with breast cancer every year, making it the most common cancer in women 
worldwide and the second leading cause of cancer mortality in women (Sun et al. 2017). 
The majority of breast cancers are of epithelial origin (carcinoma) and start from ductal 
hyperproliferation, with malignant connective tissue tumours (sarcomas) forming a negligible minority. 
Breast carcinomas have the potential to metastasize and can commonly transfer to distant organs such 
as the bones, liver, lung and brain, which mainly accounts for its mortality (Fentiman and D’Arrigo 
2004; Sun et al. 2017). 
Traditional breast cancer therapies include chemo- and radio-therapy. However, the treatment of breast 
cancer still remains a challenge due to its heterogeneous nature, which needs to be accounted for when 
choosing therapeutic options. Although more effective and individualized approaches to breast cancer 
treatment have been developed, in the past few years, there are still no targeted drugs approved for the 
most aggressive subtype — triple negative breast cancer (TNBC). The emergence of drug resistance 
also poses a threat to the successful therapy in molecular subtypes of breast cancer (BC) (Tong et al. 
2018). It is therefore imperative to explore and design novel therapy alternatives, such as 
immunotherapy, considering that the role of the immune system in the emergence of breast cancer has 
been firmly established (Makhoul et al. 2018).   
 
3.1. Breast cancer subtypes  
 
Breast cancer is a heterogenous disease and can be classified into different subtypes with distinct 
biological features and different clinical implications (Dai et al. 2015). The subtyping of breast cancer 
has been performed based on histopathology, immunohistochemistry (IHC) markers and gene 
expression profiles, through the use of microarrays.  
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3.1.1. Histopathology 
 
The histopathologic subtyping of breast carcinoma is based on its cytoarchitectural characteristics. 
Considering that it occurs in the mammary gland, the carcinoma is classified as in situ if it has not 
breached the epithelial component of the breast. Otherwise, if the carcinoma has invaded the breast 
stroma, it is considered invasive. Moreover, the carcinoma can be classified as ductal, if it originates 
from the inner lining epithelium of the ducts and lobules of the mammary gland, or lobular, if it arises 
from within the lobules that supply the ducts with milk (Dai et al. 2015). The combination of these 
features originates four different subtypes: invasive ductal carcinoma, ductal carcinoma in situ, invasive 
lobular carcinoma, and lobular carcinoma in situ. Invasive ductal carcinoma is the most common form 
of breast cancer, accounting for 50% to 70% of invasive breast cancers, while invasive lobular 
carcinoma accounts for 10% and is more likely to escape detection on mammography and physical 
examination (Alkabban and Fergunson 2019). 
 
3.1.2. Immunohistochemistry markers 
 
Breast cancer can be classified according to classical IHC markers, namely the oestrogen receptor (ER), 
progesterone receptor (PR) and the Human Epidermal growth factor Receptor 2 (HER2). Approximately 
70% of all breast cancers are ER positive, meaning that oestrogen is able to bind to the ER in tumour 
cells, stimulating their division. Hence, ER positive tumours tend to respond well to endocrine therapy, 
using ER antagonists and oestrogen-producing enzymes inhibitors (Lumachi et al. 2013; Lange and Yee 
2008). PR is expressed in over two-thirds of ER positive breast cancers and also has a role in the 
proliferation of tumour cells, in response to progesterone (Lim, Palmieri and Tilley 2016; Lange and 
Yee 2008). HER2 is an oncogene expressed in 20% to 30% of breast cancers, being associated with 
more aggressive cancers with higher recurrence and death rates. This receptor is established as a 
therapeutic target in HER2 positive patients, frequently using Trastuzumab, a monoclonal antibody, as 
a chemotherapy adjuvant (Mitri, Constantine and O’Regan 2012). 
TNBC subtype does not express any of the aforementioned markers and therefore its treatment does not 
benefit from endocrine therapy. TNBC is typically an aggressive cancer, associated with poor prognosis 
and accounting for approximately 10% to 20% of all invasive breast cancers (Aysola et al. 2013). This 
cancer subtype does not respond well to current cancer immunotherapies and is treated almost 
exclusively with surgery, chemo- and radio-therapy (Feher 2017). 
 
3.1.3. Gene expression profiling 
 
Gene expression patterns of breast carcinomas were first assessed in a pioneering study by the Sørlie 
group (Sørlie et al., 2001). Using microarrays, they were able to characterize breast carcinomas at the 
molecular level, identifying five subtypes with distinct clinical outcomes: luminal A, luminal B, HER2 
overexpression, basal and normal-like tumours. These subtypes are also associated with the IHC 
nomenclature, with exception of the latter.  
Luminal A breast cancer is the most common subtype, accounting for approximately 50% of all invasive 
breast cancers (Makki 2015). It is usually also positive for ER, PR and HER2. Luminal B breast cancer 
is the second most common subtype, accounting for 20% of all invasive breast cancers (Makki 2015). 
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Like luminal A, it is positive for ER and PR. However, only part of these tumours express HER2, and 
are usually associated with worse prognosis, relative to luminal A. In general, luminal tumours are 
associated with good prognosis, responding well to endocrine therapy but poorly to conventional 
chemotherapy (Dai et al. 2015). 
HER2 overexpressing tumours are negative for both ER and PR, and positive for HER2. These tumours, 
which are identified at the transcriptomic level, do not perfectly match tumours positive for HER2, 
identified through IHC. This subtype is associated with poor prognosis, mainly due to the fact that 
patients have a higher risk of relapsing (Dai et al. 2015).  
Basal-like is a breast cancer subtype that has a tendency to affect younger women. It is typically a TNBC, 
and, although the latter comprises a more heterogenous group of tumours, there are studies defending 
that basal-like tumours should be divided into further categories, considering that patients may have 
divergent outcomes regarding mortality rates or recurrence (Milioli et al. 2017; Liu, Zhang and Zhang 
2014). Like TNBC, the lack of hormone receptors leads to a limitation in therapeutic options, showing 
a lack of response to Trastuzumab and endocrine therapies. Thus, this subtype is usually associated with 
poor prognosis (Liu, Zhang and Zhang 1014; Makki 1015).  
Normal-like tumours are TNBC distinct from basal-like, with an intermediate prognosis between the 
latter and luminal cancers. This subtype is poorly described and its clinical relevance is yet to be 
determined, due to the fact that it could be the result of technical artefacts from normal breast tissue 
contamination (Yersal and Barutca 2014; Wesolowski and Ramaswamy 2018).   
 
3.2. The tumour microenvironment  
 
The tumour microenvironment (TME) is an important determinant of the initiation, progression and 
metastasis of cancer. It consists of a complex and dynamic niche, made of extracellular matrix and 
cellular components. The main infiltrating cells include fibroblasts, neuroendocrine, adipose, and 
immune cells. Immune cells in the TME are both from the innate and immune system (Wang et al. 
2017).  
Despite the existence of different breast cancer subtypes and patient inter-variability, recent studies 
focused on the TME have been unveiling tumour-infiltrating immune cell patterns that are either 
correlated with poor patient prognosis or good outcome (Man et al. 2013; Fridman et al. 2010). One 
example of this relationship is the association between the infiltration of lymphocytes in breast tumours 
and prognosis. Amongst tumour-infiltrating lymphocytes (TILs), NK cells are able to naturally kill 
circulating tumour cells through cytolytic activity (Wu and Lanier 2003). However, while the role of 
NK cells outside the vascular system and in the tumour microenvironment still remains unclear in most 
cancer types (Larsen, Gao and Basse 2014), the association between high levels of CD8+ T cells and 
their anti-tumour effect is well established (Maimela, Liu and Zhang 2019). On the other hand, 
regulatory T (Treg) cells present immunosuppressive functions that are able to inhibit the cytotoxic 
activity of CD8+ T cells and NK cells, thus promoting tumour growth (Maimela, Liu and Zhang 2019).   
Tumour-infiltrating T cells have already been described as a key component of the tumour 
microenvironment, due to recent clinical trials that demonstrated the ability to durably control cancer in 
some patients by manipulating them (Sharma and Allison 2015). Tumour-associated myeloid cells, 
however, remain less studied than T cells, even though they comprise a significant part of the total 
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tumour immune cell infiltrates and have already been described as potent regulators of tumour-
associated immune suppression, cell invasion and metastases (Weagel et al., 2015).  
During tumour development, tumour cells secrete several cytokines, e.g., monocyte colony stimulating 
factor (M-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) (Tang et al. 1992; 
Kerkar and Restifo 2012). GM-CSF is a key factor in the differentiation of myeloid-derived suppressor 
cells (MDSCs). MDSCs are myeloid cells of granulocytic (neutrophil-like) or monocytic (monocyte-
like) origin, induced into an immature and suppressor state. These cells are capable of not only 
supressing NK and CD8+ T cell anti-tumour activity, but also directly stimulating tumour cell 
proliferation, metastasis and angiogenesis (Kerkar and Restifo 2012; Mabuchi et al. 2018; Gonda et al. 
2017). Moreover, GM-CSF, together with M-CSF, induce the recruitment of monocytes and their 
differentiation into non-polarized (M0) macrophages (Ushach and Zlotnik 2016; Qiu et al. 2018; Tang 
et al. 1992).  
Tumour associated macrophages (TAMs) are a major component of the tumour microenvironment, 
reaching over 50% of the tumour mass in some breast cancers (Weagel et al., 2015; Qiu et al. 2018). 
Depending on the stimuli from the surrounding TME, macrophages are polarized into classically 
activated (M1) or alternatively activated macrophages (M2) and exert dual influences on tumourigenesis 
by either enhancing anti-tumour responses or by manifesting tumour-promoting activities, respectively. 
M2 macrophages have already been described as being potent regulators of tumour-associated immune 
suppression, cell invasion and metastasis. M2 macrophages aid in the process of angiogenesis, allowing 
new blood vessel growth, which feeds the malignant mass of cells (Weagel et al., 2015). Thus, their 
presence in tumour masses can be an indicator of poor prognosis in numerous cancer types, including 
breast cancer (Weagel et al., 2015; Cotechini, Medler and Coussens 2015; Gonda et al. 2017).  
On the other hand, M1 macrophages are able to induce tumour-regression, through contact-dependent 
phagocytosis and cytokine production, and are usually associated with good prognosis (Poh and Ernst 
2018). The contrasting roles of TAMs in breast cancer makes them an active topic of research, with the 
prospective of using these cells as targets in cancer immunotherapy, either by reducing the numbers of 
M2 macrophages and/or inducing re-polarization towards a M1 phenotype (Poh and Ernst 2018).  
 
3.2.1. Immunosenescence and macroph-ageing 
 
Throughout the course of life, the immune system keeps surveilling the organism for foreign pathogens, 
such as bacteria and viruses, and pre-cancerous and cancerous cells. This is a process known as 
immunosurveillance (Smyth, Dunn and Schreiber 2006). However, there is a gradual decline of the 
immune system with age, which is defined as immunosenescence (Zinger, Cho and Ben-Yehuda 2017). 
This deterioration leads to alterations in the proportion of different immune cell types in the organism 
and in their capabilities, including a decrease in the number of naïve CD8+ and CD4+ T cells (Pawelec 
2017), impaired function of mature lymphocytes, and a decrease in the number and the phenotypic 
alteration of natural killer (NK) cells (Zinger, Cho and Ben-Yehuda 2017; Montecino-Rodriguez, 
Berent-Maoz and Dorshkind 2013). There is also evidence for an increase in myeloid-lineage cells 
(Montecino-Rodriguez, Berent-Maoz and Dorshkind 2013), which is coupled with reduced anti-tumour 
activity in macrophages and their predisposition for a pro-tumour phenotype (Figure 3.1) (Provinciali et 
al. 2017). 
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Figure 3.1 Schematic representation of immune cell immunosenescence-related changes. Adapted from Costantini, D'Angelo, 
and Reale 2018. 
 
Macroph-ageing was defined by the Franceschi group (Franceschi et al. 2006) as the chronic 
macrophage activation, one of the major factors responsible for the pro-inflammatory state associated 
with ageing. Macroph-ageing and inflamm-ageing occur in association with immunosenescence, and 
lead to the reduction in the efficacy of the immune response, resulting in decreased immunosurveillance 
and anti-tumour effector function (Costantini, D'Angelo, and Reale 2018). 
Increasing breast cancer rates with ageing have already been associated with immunosenescence. This 
association might not only impact the incidence and progression of breast cancer, but also the 
effectiveness of immunotherapy due to compromised immunosurveillance (Provinciali et al. 2017). The 
efficacy of more traditional cancer therapies, such as chemo- and radio-therapy, may also be impacted, 
given that they are at least partially dependent of tumour-specific immune responses and their ability to 
bring back immunosurveillance (Bracci, Schiavoni and Sistigu 2013; Kroemer et al. 2015). Therefore, 
the characterization of tumour-infiltrating immune cells may disclose better strategies for overcoming 
immune suppression and restoring immunosurveillance. 
 
4. Single-cell transcriptomics 
 
In the 17th century, Robert Hooke first used a microscope to describe little boxes distinct from one 
another in cork, which he named cells (Hooke 1665). Today, it is universally accepted that the cell is 
the unit of life, all cells come from pre-existing cells and all living organisms are composed of different 
cell types that share common basic features, but may vary vastly in their function and molecular profile 
(Feher 2017). 
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It is important to assess this cell heterogeneity in order to understand fundamental biological processes 
in health and disease, allowing for the improvement of existing therapies and the discovery of new ones 
(Hwang, Lee and Bang 2018). One way to do this is through single-cell RNA sequencing (scRNA-seq). 
scRNA-seq was first described in 2009 by Tang et al. and has since been gaining widespread popularity 
as a method to survey the diversity of cell types within a tissue sample. Its underlying principles are the 
same as in bulk RNA-sequencing (RNA-seq), an approach that uses sequencing technologies to profile 
the transcriptome, i.e., the complete set of RNA molecules in a biological sample, thereby allowing to 
quantify and assess differential gene expression between conditions of interest (Wang, Gerstein and 
Snyder, 2009). However, common bulk RNA-seq experiments measure gene expression levels as 
averages across populations of cells, under the assumption that tissues are composed of homogeneous 
populations of cells, only allowing the characterization of population-level gene expression. These 
methods are therefore insufficient for studying heterogeneous cellular systems due to the likelihood of 
missing important cell-to-cell variability (Hwang, Lee and Bang 2018). scRNA-seq experiments 
measure the distribution of expression levels for each gene in each cell, allowing to characterize a 
population of individual cells and to better understand gene expression patterns in complex 
heterogeneous tissues (Wang et al. 2018). 
Although the development of scRNA-seq protocols was motivated by the need to study conditions where 
only a small amount of material was available, such as cells from the early embryonic development, 
protocol improvements and massively parallel sequencing platforms boosted an increase in the number 
of cells studied in these analyses, ranging from only a few cells to hundreds of thousands of single cells 
per study (Figure 4.1) (Tang et al. 2009; Svensson, Vento-Tormo and Teichmann 2018). This continuous 
evolution is radically improving the dissection of heterogeneity within cell populations, with many 
applications in diverse fields. One example is the deconvolution of highly diverse immune cell 
populations in health and disease (Hwang, Lee and Bang 2018; Papalexi and Satija 2017), which has 
been applied in the cancer research field, by enabling the estimation of specific immune cell composition 
of solid tumours (Schelker et al. 2017), and in the neurosciences research field, by allowing the 
characterization of neuronal and non-neuronal cell diversity across multiple human brain regions 
(Spaethling et al. 2017; Darmanis et al., 2015).  
 
Figure 4.1: Scaling up of scRNA-seq experiments. From Svensson, Vento-Tormo and Teichmann 2018. 
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4.1. The technology of single-cell RNA sequencing 
 
Every scRNA-seq experiment shares a common basic strategy, starting with tissue dissociation, sorting 
and isolation of single cells, followed by reverse transcription of mRNA, amplification of cDNA and, 
finally, library preparation and sequencing. Like in bulk RNA-sequencing, most protocols use the 
Illumina platform for sequencing. Thus, the major difference between bulk RNA-seq and scRNA-seq 
protocols is the sorting step.   
There are several methods that can be used to sort cells, including the ones that capture only a small 
number of cells with high level of supervision, such as micromanipulation and laser capture 
microdissection (LCM), and automatic microfluidic methods which focus mainly on high throughput 
(Figure 4.2).  
Micromanipulation consists of using microscope-guided capillary pipettes to extract single cells, while 
LCM uses a laser to attach individual cells from a tissue to a thin film that can be eliminated afterwards. 
These low throughput methods have the advantage of ensuring that only one cell is captured at a time, 
and allow the verification of cell viability and morphologic features through microscopic supervision 
(Kolodziejczyk et al. 2015). 
Microfluidic platforms, on the other hand, allow sorting hundreds of single cells in each run. They 
consist of using integrated fluidic circuits to capture cells and isolate them in individual channels. Cell 
capture is followed by automated reverse transcription and pre-amplification in nanoliter volumes, 
which allows to control for reagent costs. One of the most common microfluidic platforms is the 
Fluidigm C1 (Gong, Do and Ramakrishnan 2018). However, this method possesses several restrictions, 
such as the limited size of the capturing sites, which implies that cells must also be relatively 
homogenous in size, and the low yield of captured cells, considering the need to input at least 1,000 
cells to recover 96 per chip. To surpass these limitations, micro-droplet-based microfluidic platforms 
were developed. These do not use capturing sites, but instead encapsulate cells in oil droplets, together 
with the reagents needed for reverse transcription and amplification. Micro-droplet technologies, such 
as the 10X Genomics chromium system (See et al. 2018), are gaining popularity in the scRNA-seq field, 
due to escalating captured cell numbers up to thousands of cells per run, while also increasing yield up 
to 50% (Kolodziejczyk et al. 2015; Gong, Do and Ramakrishnan 2018). 
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Figure 4.2: Steps of a scRNA-seq protocol with different experimental approaches. From Kolodziejczyk et al. 2015. 
 
4.1.1. Number of cells vs sequencing depth 
 
The high number of samples used in scRNA-seq means that these assays usually involve a trade-off 
between the number of cells and sequencing depth, i.e., the number of RNA transcripts sequenced per 
cell. There is a direct dependence of cell type classification on sequencing depth, meaning that the 
resolution with which we are able to distinguish different cell types is dependent on the depth of cellular 
profiling (Streets and Huang 2014).  
Previous systematic analyses of how the transcriptional identity of a cell is preserved, as sequencing 
depth is decreased, concluded that a majority of the primary genes that contribute to transcriptional 
variance among diverse types of cells are identified by low-coverage sequencing analysis, preserved in 
sequencing depths as low as 10,000 reads per cell. Cells with subtle transcriptional differences, such as 
neural cells at different stages of development, are distinguishable with a sequencing depth of about 
50,000 reads per cell (Figure 4.3) (Streets and Huang 2014). 
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Figure 4.3: Relationship between sequencing depth and cell type identification. Resolution of different cell types and states 
increases with sequencing depth. Cells from different organs can be distinguished with less than 10,000 reads, while cells from 
the same type and at different stages of development can be identified with about 50,000 reads per cell. Adapted from Streets 
and Huang 2014. 
 
Nevertheless, accurate estimation of sequencing depth per experiment should take into account both 
total mRNA content in individual cells and the diversity of mRNA species in those cells. Different 
scRNA-seq protocols with different cell number and sequencing depth capacities can be used in an 
integrated approach, whereby complex tissues are first discriminated using low-depth droplet-based 
technologies to identify new and/or rare populations of interest and their associated markers. 
Subsequently, these markers can be used for enrichment and deep sequencing using high-depth and low 
throughput approaches (Baran-Gale, Chandra and Kirschner 2017; Papalexi and Satija 2018).  
 
4.2. Computational analysis 
 
In scRNA-seq, each library represents a single cell rather than a population of cells, as is the case for 
bulk RNA-seq. Working with minute amounts of mRNA means that only 10%–20% of transcripts in a 
cell get reverse transcribed, leading to high technical noise, especially noticeable in lowly expressed 
genes (Kolodziejczyk et al. 2015).  
The sources of discrepancy between libraries arise mostly from amplification bias and gene dropouts. 
Dropouts occur when a gene is expressed at moderate level in one cell, but fails to be captured in another 
cell, usually due to failures in reverse transcription. This binary modality in gene expression associated 
with zero-inflation is usually modelled in methods developed specifically for scRNA-seq data analysis 
(Sekula, Gaskins and Datta 2019).  
Given that scRNA-seq is a relatively recent technology, currently there is still no gold standard pipeline 
to analyse this type of data. This leads to an underlying challenge in scRNA-seq data analysis, 
considering the vast variability between different datasets regarding experimental design, number of 
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cells and sequencing depth. Therefore, scRNA-seq pipelines should be adapted for each individual 
dataset in terms of quality controls measures and statistical tools.  
However, it is possible to pre-define a few typical sequential steps in scRNA-seq data analysis. These 
include quality control to remove poor quality samples, followed by normalization for library sizes, 
correction of technical confounders, and clustering to identify groups of cell types and/or states 
(Kolodziejczyk et al. 2015).  
Dimensionality reduction techniques are also commonly used to perform exploratory analysis of 
scRNA-seq data, as these data are typically high-dimensional. Two of the most common dimensionality 
reduction techniques are principal component analysis (PCA) (Jolliffe and Cadima, 2016) and t-
distributed stochastic neighbour embedding (t-SNE) (van der Maaten and Hinton, 2008). 
In PCA, the original variables are substituted by a new set of uncorrelated variables. These are 
designated as principal components, and consist of linear combinations of the original variables. Of all 
the possible linear combinations, for each case, the one with the maximum variance is selected, given 
that the principal components should explain a major part of the variance associated with the original 
variables. Hence, the variance of each principal component is a measure of the quantity of information 
explained by it. Dimensionality reduction is obtained by considering only the principal components that 
are associated with the higher variance, resulting in small information loss (Jolliffe and Cadima, 2016).  
t-SNE, on the other hand, is a nonlinear dimensionality reduction.  This method consists of defining a 
similarity probability distribution over pairs of objects in high-dimensional space, and calculating the 
probability of similarity of points in the corresponding low-dimensional space. It then tries to minimize 
the difference between similarities in high- and low-dimensional space, by using the Kullback-Leibler 
divergence (Pavlichin and Weissman, 2016), a measure of how one probability distribution diverges 
from a second expected probability distribution. This results in the mapping of the data to a lower 
dimensional space and allows the identification of clusters based on similarity of data points with 
multiple features. However, unlike PCA, the input variables are no longer identifiable (van der Maaten 
and Hinton, 2008). 
The remaining downstream analyses vary according to the biological question under study. For example, 
one might be interested in finding marker genes that distinguish different cell types from each other, for 
which a classic differential expression analysis suffices (Alessandrì, Arigoni and Calogero 2019). 
Another possibility would be to study the alteration of states of a given cell type between two conditions, 
e.g., microglia in healthy and microglia in AD-affected brains, which would refer us to differential state 
analysis (Crowell et al. 2019). In this work, we focused on constructing scRNA-seq data analysis 
pipelines by combining the best approaches and necessary quality metrics for each analysed dataset, 
with the general goal of finding marker genes of different cell types and performing cell type 
deconvolution of bulk RNA-seq datasets. 
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5. Objectives 
 
5.1. Single-cell RNA sequencing of the brain 
 
The existing knowledge on the extent of cell type diversity in the mammalian brain remains incomplete 
(Tasic et al. 2016), as remains the estimation of the relative cell type abundance in the nervous system, 
which is considered an important approach to understand neurological disease and ageing. Indeed, many 
studies have described a large number of neurological diseases implicating abnormal glial cell numbers 
(von Bartheld, Bahney, and Herculano-Houzel 2016) and also a loss or functional alteration of astrocytes 
and microglia associated with ageing, which is itself an important risk factor for the onset and 
progression of neurodegenerative disorders, such as Parkinson’s and Alzheimer’s diseases (Joe et al. 
2018; Keren-Shaul et al. 2017; González-Reyes et al. 2017). 
As shown by this project’s host laboratory at iMM, led by Nuno Barbosa Morais, through a preliminary 
gene expression analysis of post-mortem prefrontal cortex samples of sporadic PD and non-PD 
individuals, there is an expected loss of neurons and a specific accentuation in glial cells of the systemic 
molecular effects of the disorder reported for brain tissues (activation of inflammation and immune 
response pathways and lower activity of metabolic ones). 
Therefore, our first goals are to: 
a. Obtain the gene expression signatures of the major brain cell types; 
b. Unveil how the relative abundance of neurons and glia in the brain correlate with 
ageing and neurological health. 
 
5.2. Single-cell RNA sequencing of tumour-infiltrating immune cells 
 
There is an urge to characterise the anti-cancer myeloid compartment of the tumour microenvironment 
and understand the complexity of the mechanisms involved in myeloid regulation (Elliot et al. 2017). 
At the same time, age-associated changes in the tumour-infiltrating immune landscape and the 
consequence of immunosenescence are still poorly described in breast cancer. Moreover, most 
immunotherapy pre-clinical experiments are performed in young mice, leading to the suggestion that 
successful treatments may be age-dependent and biased towards younger subjects (Zinger, Cho, and 
Ben-Yehuda 2017). 
All of these considered, the second overall aim of this project is to unbiasedly characterise cellular 
heterogeneity in the tumour microenvironment, focusing on the context of breast cancer, while also 
unveiling the variability of infiltration patterns with age and prognosis. 
Particularly, we aim at: 
a. Evaluating the cellular diversity and molecular signature of TAMs; 
b. Understanding how the intra-tumoural diversity and functionality of infiltrating 
immune cell types is associated with age and prognosis. 
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6. Methods 
 
R programming language (ver. 3.6.1) (R Core Team 2019), with several Bioconductor packages (ver. 
3.9) (Huber et al., 2015) and packages from The Comprehensive R Archive Network (CRAN), was used 
to perform most downstream steps, including quality control, visualization, normalization, feature 
selection, clustering and differential expression analysis.  
 
6.1. Single-cell RNA sequencing of the brain 
 
6.1.1. Datasets 
 
Table 6.1: Summarized description of the datasets used in the first part of the analysis. 
ID Manuscript 
designation 
Database Technology Format Samples 
phs000835.v7 Spaethling dbGAP* scRNA-seq FASTQ 506 
GSE67835 Darmanis GEO** scRNA-seq Count matrix 247 
GSE73721 Zhang GEO scRNA-seq Count matrix 29 
phs000424.v7.p2 GTEx GTEx*** RNA-seq Count matrix 2,467 
GSE125583 Alzheimer’s disease GEO RNA-seq Count matrix 289 
GSE68719 Parkinson’s disease GEO RNA-seq Normalized 
count matrix 
57 
* database of Genotypes and Phenotypes (Mailman et al. 2007). 
** Gene Expression Omnibus (Clough and Barrett 2016). 
*** The Genotype-Tissue Expression (Lonsdale et al. 2013). 
 
The phs000835.v7 dataset, here referred as the Spaethling dataset, consists of healthy tissue samples 
from adult human brain biopsies collected from patients at the time of surgery and then further cultured 
up to 84 days in vitro. Biopsies were performed in different brain areas: hippocampus, left and right 
frontal cortex, left temporal lobe, right middle temporal gyrus, left primary motor cortex and right 
cerebellum. Single-cells were sorted using microcapillary pipette aspiration and snap frozen until 
processing. Each single-cell’s RNA was amplified and prepared for sequencing, following the TruSeq 
stranded library generation without the initial fragmentation step. Samples were deep paired-end 
sequenced with either an Illumina HiSeq 2500 or a NextSeq 500 machine. Out of the 506 cells, 73 were 
labelled by the authors as astrocytes, 30 as microglia, 136 as neurons, 4 as oligodendrocytes, 38 as 
endothelial cells and 229 samples were left as unidentified brain cells. We extracted the paired FASTQ-
files from the SRA-raw files using the fastq-dump program of the SRAtoolkit (Leinonen, Sugawara and 
Shumway, 2010). We then quantified transcript abundances against a reference transcriptome using the 
pseudoaligment tool Kallisto (Bray et al. 2016).  
The GSE67835 dataset, here referred as the Darmanis dataset, consists of healthy tissue samples from 
8 adult human brain cortex biopsies. Single cells were sorted using the Fluidigm C1 platform. Each 
single-cell’s RNA was amplified and prepared for sequencing using the Nextera XT DNA Sample 
Preparation Kit. Samples were sequenced with an Illumina NextSeq instrument (2x75 bp) with an 
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average of 2,838,000 reads per cell. Reads were aligned using STAR (Dobin et al. 2012) and per gene 
counts were calculated using HTSEQ (Darmanis et al. 2015). Quality control of the Darmanis dataset 
was previously performed in-house, using the same quality control metrics applied in this work. Out of 
247 cells, 62 were labelled as astrocytes, 16 as microglia, 131 as neurons and 38 as oligodendrocytes. 
The GSE73721 dataset, here referred as the Zhang dataset, consists of healthy tissue samples from 
adult human and mouse brain temporal lobe cortex biopsies. Single cells were sorted using 
micromanipulation coupled with cell type specific antibodies (Zhang et al. 2016). Each single-cell’s 
RNA was amplified and prepared for sequencing using the Next Ultra RNA-seq library prep kit for 
Illumina. Libraries were sequenced using the Illumina NextSeq sequencer (2x150 bp). Out of the 29 
cells used in this project, 12 were labelled by the authors as human mature astrocytes, 3 as myeloid cells 
(microglia), 4 as mouse mature astrocytes, 1 as human mature neuron, and 5 as human mature 
oligodendrocytes (Zhang et al., 2016). 
The phs000424.v7.p2 dataset, here referred as the GTEx dataset, was obtained from the GTEx project, 
a resource database and associated tissue bank with relevant clinic metadata (The GTEx Consortium, 
2013). This dataset consists of 2,467 bulk RNA-seq samples from several neural tissues, namely, 
amygdala, anterior cingulate cortex, caudate (basal ganglia), cerebellar hemisphere, cerebellum, cortex, 
frontal cortex, hippocampus, hypothalamus, nucleus accumbens (basal ganglia), putamen (basal 
ganglia), spinal cord (cervical c-1) and substantia nigra. Libraries were prepared using the Illumina 
TruSeq RNA protocol (2x76 bp), and sequenced with the Illumina HiSeq 2000 platform, averaging ~50 
million aligned reads per sample. 
The GSE125583 dataset, here referred as the Alzheimer’s disease dataset, consists of 242 samples of 
post-mortem fusiform gyrus from Alzheimer's disease patients, and 126 controls, i.e. samples of 
fusiform gyrus of neurologically normal age-matched controls. This dataset was available as a raw count 
matrix (Srinivasan et al., 2019). Reads were aligned with GSNAP (Wu et al. 2016) and reads per gene 
were counted with the HTSeqGenie Bioconductor package (Pau and Reeder, 2014). 
The GSE68719 dataset, here referred as the Parkinson’s disease dataset, consists of samples of post-
mortem prefrontal cortex (BA9) tissue obtained from 29 Parkinson’s disease patients and 44 healthy 
controls. Samples were sequenced on an Illumina HiSeq2000 instrument (2x101 bp). This dataset was 
available as a DESeq2 normalized count matrix (Dumitriu et al. 2015). To avoid having age as a 
confounding factor, we selected only samples from patients over 64 years of age, resulting in 29 PD 
samples and 28 non-PD samples.  
 
6.1.2. Normalization 
 
Normalization of library sizes of scRNA-seq datasets was performed using a deconvolution-based 
scaling method, available as the computeSumFactors function in the package scran (Lun, Bach and 
Marioni 2016).  
Normalization for the correction of batch effects of scRNA-seq datasets was performed using the 
removeBatchEffect function, available in Bioconductor/R-package limma (Ritchie et al., 2015). This 
method fits a linear model to the data and removes the component related to the batch effects (Ritchie 
et al. 2015). 
Normalization of library sizes of bulk RNA-seq datasets was performed using the voom method, which 
estimates the mean-variance relationship of the log-counts and generates a precision weight for each 
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observation. This method is available as the voom function in Bioconductor/R-package limma (Ritchie 
et al., 2015).  
 
6.1.3. Feature selection 
 
Feature selection, also known as variable selection, consists of selecting a subset of meaningful and 
relevant features, reducing data dimension before performing predictive analysis. This allows to 
improve efficiency in classification models, reduce computation complexity, and boost the 
generalization ability of the model to external datasets (Lai et al., 2017). 
We tested two different methods for feature selection, identification of highly variable genes (HVG) and 
identification of high dropout genes (HDG).  
Identification of HVG was applied using the Brennecke_getVariableGenes function with default 
parameters, included in the M3Drop package (Andrews 2019). This function corrects for the relationship 
between variance and mean expression by normalizing library sizes and calculating the mean and the 
squared coefficient of variation (SCV). HVG are selected by fitting a quadratic curve to the relationship 
between the mean and SCV, and using a chi-squared test to find genes significantly above the curve 
(Brennecke et al. 2013). 
Identification of HDG was applied using the M3DropDifferentialExpression function with default 
parameters, available in the M3Drop package (Andrews 2019). This method models the non-linear 
relationship between dropout rates and average gene expression, using a Michaelis-Menten equation, 
considering that dropouts occur during reverse transcription, an enzyme reaction whose kinetics are 
thereby modelled. HDG are identified as being shifted above the expected curve (Andrews and Hemberg 
2018). 
 
6.1.4. Pseudotime analysis 
 
To analyse different states of development, we used the Monocle package (Trapnell et al. 2014) to build 
a neural cell trajectory, in which cells were ordered by pseudotime, i.e., a measure of how much progress 
an individual cell has made through a process such as cell differentiation.  
We began by using the function setOrderingFilter to mark the genes used in the analysis, in this case, 
the set of HDG identified using the M3Drop package. This was followed by reducing the dimensionality 
of the dataset, with the reduceDimension function, with method DDRTree. Finally, cells were ordered 
with the orderCells function, which calculates where each cell falls within that trajectory, using a 
reversed graph embedding machine learning method to learn the sequence of gene expression changes. 
Thus, this trajectory is associated with the total amount of transcriptional change that a cell undergoes 
as it moves from the starting state to the end state (Trapnell et al. 2014). 
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6.1.5. Clustering 
 
We used the sc3 function from the SC3 package (Kiselev et al. 2017) to perform unsupervised clustering 
of single neuronal and glia cells. The ks parameter (number of clusters) was defined as seven, 
considering this was the smallest number of ks for which there was separation of neurons and microglia 
into distinct clusters. Working as a consensus clustering tool, this method uses a parallelisation approach 
to evaluate different clustering parameters simultaneously, e.g., the set of Euclidean, Pearson and 
Spearman distances. Finally, it combines the different clustering results into a consensus matrix that 
demonstrates the probability of a cell belonging to a given cluster (Kiselev et al. 2017). 
 
6.1.6. Marker genes  
 
We tested three different methods for obtaining marker genes that could discriminate each cell subset, 
implemented in the PAMR (prediction analysis for microarrays) (Tibshirani et al. 2002), SC3 (Kiselev 
et al. 2017) and Caret (Classification And REgression Training) packages (Kuhn, 2019).  
PAMR uses the nearest shrunken centroid classification, which consists of computing a standardized 
centroid for each class/cell type, by averaging gene expression for each gene in each class and dividing 
it by the within-class standard deviation for that gene. Each of the centroids is shrank towards 0, by an 
amount defined as the threshold. This reduces the effect of noisy genes and performs automatic selection 
of marker genes (Tibshirani et al. 2002). The implementation of this method follows a sequential use of 
the available functions, starting with the pamr.train function, which receives the count matrix as input 
and trains the nearest shrunken centroid classifier. Next, we use pamr.cv to cross-validate the classifier 
and pamr.fdr to estimate false discovery rates. Finally, pamr.listgenes outputs a list of marker genes 
based on the user-defined parameter t (threshold). We chose t as the value that allowed the utilization of 
the least number of marker genes possible, while retaining a high accuracy of classification (> 90%), 
along with False Discovery Rate (FDR) = 0.   
The method implemented in the SC3 function get_marker_genes (Kiselev et al. 2017), that enables the 
discovery of marker genes for each cell type, consists of building a binary classifier for each gene based 
on the mean expression values of each cluster. The area under the receiver operating characteristic 
(AUROC) curve is used to quantify the accuracy of the classifier and a p-value is calculated for each 
gene using the Wilcoxon signed rank test. For the analysis of neuronal and glia cells, we defined an 
auroc.threshold > 0.75 and p.val < 0.05, with a maximum of 200 marker genes for each cell type 
(Kiselev et al. 2017). 
The Caret package comprises a set of functions applied in predictive modelling. For this project, we 
focused on elastic nets, a type of regularized logistic regression (Kuhn, 2019). This method linearly 
combines two regularization parameters, the L1 (λ) and L2 (α) penalties of the lasso (least absolute 
shrinkage and selection operator) and ridge methods, respectively. High values of λ lead to many 
coefficients being zeroed, thus performing feature selection (Waldmann et al. 2013). We implemented 
this method using the train function, with the method parameter defined as “glmnet”. 
 
 
22 
 
6.1.7. Cell type deconvolution 
 
Deconvolution algorithms make use of specific cell types’ gene signatures expected to be contained in 
a heterogeneous tissue sample, such as is the case for the expected different cell types in brain samples, 
to estimate their cell fractions within the tissue. This is performed assuming that the gene expression 
profile of a given tissue is the convolution of the gene expression levels of the different cells that 
constitute it (Finotello and Trajanoski 2018).  
 
We used CIBERSORT (Newman et al. 2019) to perform neuronal and glia cell type deconvolution of 
bulk RNA-seq brain samples. CIBERSORT uses linear support vector regression to characterize cell 
type composition of complex tissues from their gene expression profiles (Newman et al. 2019). 
 
6.2. Single-cell RNA sequencing of tumour-infiltrating immune cells 
 
6.2.1. Datasets 
 
Table 6.2: Summarized description of the datasets used in the second part of the analysis. 
* The Cancer Genome Atlas (Tomczak et al. 2015; Weinstein et al. 2013). 
 
The GSE114725 dataset, here referred to as the Azizi dataset, consisted of scRNA-seq of breast tumour-
infiltrating immune cells (Azizi et al. 2018). Immune cells were obtained from 8 different 
patients/tumours and also from patient’s blood, lymph node, and normal tissue. For this project, only 
the tumour-infiltrating immune cells were used, comprising a total of 21253 cells. The tumours are 
represented across several subtypes, namely ER positive, PR positive, HER2 positive and TNBC. 
Single-cells were previously sorted using FACS and droplet technology, and sequenced using Illumina 
HiSeq 2500 instruments with paired-end sequencing (PE1 54 bp and PE2 66 bp). Each cell was covered 
by an average of 22,000 reads. Quality control was performed using FASTQC (Andrews, 2010). 
Libraries that displayed significant (> 25%) low quality bases were re-sequenced to make sure samples 
were comparable in the downstream analysis. The count matrix was generated using package SEquence 
Quality Control (SEQC) (Azizi et al. 2018). Poor quality cells were filtered using the usual quality 
metrics, library size, number of unique features detected and percentage of mitochondrial genes. This 
generated a count matrix that was the starting point of the analysis performed in this project.  
 
ID Manuscript 
designation 
Database Technology Format Samples 
GSE114725 Azizi GEO scRNA-seq Count matrix 21,253 
- TCGA TCGA* RNA-seq Count matrix 878 
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Table 6.3: Clinical metadata of the Azizi dataset. Adapted from Azizi et al. 2018. 
 
 
The TCGA dataset consisted of bulk RNA-seq of breast tumours, as well as clinical data for 878 
samples. These data were obtained from the data portal of TCGA, a project aimed at cataloguing cancer 
genomic profiles (Tomczak et al. 2015; Weinstein et al. 2013). Age information was only available for 
756 samples. Count matrices were normalized in-house using the voom function from the limma package 
(Ritchie et al., 2015).  
 
6.2.2. Normalization 
 
Normalization of the Azizi dataset was performed using the computeSumFactors function, available at 
the scran package (Lun, Bach and Marioni 2016). The following analysis was performed using the 
Seurat package (Stuart et al. 2019), which is optimized for analysis of large scRNA-seq datasets.   
 
6.2.3. Feature selection and data scaling 
 
Identification of HVG was performed using the FindVariableFeatures function, with default parameters 
(Stuart et al. 2019). This method returned 2,000 features ranked by standardized variance, which 
represents a measure of single cell dispersion after controlling for mean expression (Stuart et al. 2019). 
In order to avoid dominance of highly-expressed genes in downstream analysis, we used function 
ScaleData (Stuart et al. 2019) to shift and scale the expression of each gene across cells, resulting in a 
mean equal to 0 and variance equal to 1. 
 
6.2.4. Clustering 
 
Clustering of the Azizi dataset consisted of sequentially applying three Seurat functions, namely 
runPCA, FindNeighbors and FindClusters (Stuart et al. 2019). runPCA performs linear dimensional 
reduction on the dataset. The obtained principal components scores are used as input by the 
FindNeighbors function, with each of the 10 first PCs representing a combination of correlated features. 
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This method implements a KNN (K-nearest neighbor) graph-based clustering approach, using the 
Euclidean distance in PCA space. Finally, clustering of cells is performed using the FindClusters 
function, which applies a modularity optimization technique, i.e., a measure of the strength of division 
of graphs into modules, to group cells together (Stuart et al. 2019). In order to use this function, we 
chose the resolution parameter, i.e., the level of detail of the clustering analysis, considering that the 
higher the resolution parameter, the higher the number of clusters obtained. Thus, we chose an 
intermediate value of 0.5 for the whole tumour-infiltrating immune cell dataset, which returned 17 
clusters, an approximate number of the 19 originally labelled cell types and subtypes. For the clustering 
of the macrophage subset, which consisted of less than 3,000 cells, we expected two major polarizations. 
Hence, to avoid over-clustering, we used a lower value of resolution, 0.1, returning 3 clusters.  
 
6.2.5. Marker genes 
 
To identify marker genes for each cluster of the macrophage subset, we used the FindMarkers function 
(Stuart et al. 2019), comparing each cluster against the other two (cluster 0 vs. clusters 1 and 2, and so 
on). Using the test.use parameter, we selected the MAST (Model-based Analysis of Single-cell 
Transcriptomics) method to perform differential expression, which in turn utilizes the MAST package 
(Finak et al. 2015) to run the differential expression analysis. MAST uses a generalized linear model 
that accounts for the typical bimodal data of scRNA-seq datasets (with either strongly non-zero or non-
detectable expression) and stochastic dropouts, which result in sparse count matrices (Finak et al. 2015). 
 
6.2.6. Estimation of relative immune cell type proportions 
 
To infer immune cell type relative abundance of bulk RNA-seq breast tumours, we used CIBERSORT. 
This step enabled the use of a microarray-derived gene signature, the LM22 (Chen et al. 2018), to 
perform immune cell type deconvolution of the TCGA breast tumour datasets, while minimizing batch 
effects as a source of confounding technical variation. LM22 is a gene signature consisting of 547 genes 
that distinguish 22 human hematopoietic cell subsets, including different subsets of T cells, 
macrophages, B cells, dendritic cells, mast cells, eosinophils and neutrophils (Chen et al. 2018). 
 
6.2.7. Survival analysis 
 
TCGA samples were divided based on estimated proportions of CD8+ T cells and M2 macrophages. 
The significance of differences in prognostic was estimated using Kaplan−Meier plots and log-rank 
tests, using R package survival (Therneau, 2015). 
Kaplan-Meier estimates, applied in survival analysis, consist of measuring the number of subjects who 
survived over a period of time, starting from a defined point, such as cancer diagnosis, until the 
occurrence of the event, i.e., death. The Kaplan-Meier survival curve is defined as the probability of 
surviving in a given length of time. This method also allows not to exclude censored events, for example, 
when some of the subjects may not experience death before the end of the study, by considering that 
these patients have the same survival prospects as those who continue to be followed (Kishore, Goel 
and Khanna, 2010).  
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6.2.8. Differential gene expression analysis 
 
We selected two groups of TCGA breast tumour samples for differential expression analysis: those with 
relatively high proportion of CD8+ T cells and low proportion M2 macrophages, and vice-versa. The 
criteria for the selection of each group was based on the results of the immune cell type deconvolution 
analysis. For the first group, we used a cut-off of a relative proportion of CD8+ T cells > 0.15 and a 
relative proportion of M2 macrophages < 0.12, selecting 7 samples. For the second group, we used a 
cut-off of a relative proportion of M2 macrophages > 0.44 and a relative proportion of CD8+ T cells < 
0.05, selecting 7 samples (Supplementary figure 10.1).  
Differential expression analysis was performed using the limma package (Ritchie et al., 2015), following 
three main steps. These included creating a design matrix distinguishing the previously selected groups 
by using R function model.matrix, fitting the model to obtain the pooled variance, using the lmFit 
function, and computing the moderated contrast t-test and B statistic (the log-odds that a gene is 
differentially expressed), using the eBayes function (Ritchie et al., 2015)..  
 
6.2.9. Gene Set Enrichment Analysis 
 
Gene Set Enrichment Analysis (GSEA) (Subramanian et al. 2005) was performed using the desktop 
application. We used a previously ranked list of genes, ordered by decreasing moderated t-statistic, 
derived from the differential expression analysis of breast tumour samples with relatively high and low 
content in CD8+ T cells and M2 macrophages. We excluded any differentially expressed genes from 
the list that were also part of the LM22 gene signature, to avoid possible biases resultant of the immune 
cell type deconvolution analysis. We ran the analysis using the Molecular Signatures Database 
(MSigDB) hallmark gene set collection (Liberzon et al. 2015). Gene sets with a with FDR < 0.1 were 
considered significant. 
 
7. Data Analysis  
 
7.1. Obtaining the gene expression signatures of the major brain cell types 
 
7.1.1. Quality control and normalization 
 
scRNA-seq can be affected by multiple technical artefacts arising from cell sorting, library preparation, 
and sequencing. Quality control to discard poor quality cells is therefore essential for reliable 
downstream analysis, ensuring that the biological signal of interest is not obscured by technical effects. 
Library size and the number of unique features detected are two quality metrics that can be used to find 
outliers.  
The Spaethling dataset is a high-depth scRNA-seq dataset, with a median of 12,385,422 counts and 
16,084.5 unique features detected per cell. If the detection rates were equal for all cells, we would expect 
to see an approximately normal distribution for these measures. Plotting the histograms for these 
measures revealed a left tail of cells with relatively small library sizes and few expressed genes (Figure 
26 
 
7.1). This is likely associated with failure to capture and convert RNA into cDNA during library 
preparation, hence, we discarded samples with library size lower than 1,000,000 counts and number of 
unique features detected inferior to 5,000. 
 
 
Figure 7.1: Histograms of the library sizes (total_counts, top panels) and the number of unique features detected 
(total_features, bottom panels) in all cells of the Spaethling dataset. The filter cut-offs are indicated by the red lines. 
 
The percentage of mitochondrial genes is also an important quality metric to consider. Lysed cells lose 
cytoplasmic RNA, while the mitochondrial transcripts remain within the intact mitochondria. Apoptotic 
cells express mitochondrial genes and export these transcripts to the cytoplasm. Cells that show an 
increased expression of mitochondrial genes likely represent a group of dying cells. In this dataset, we 
filtered cells that showed over 25% of mitochondrial genes (Figure 7.2A). The original dataset also 
included mitochondria, which were used as positive controls, having 100% of mitochondrial genes 
(leftmost and uppermost point/cell in Figure 7.2A).  
Another alternative to perform quality control consists of using the scater package to conduct PCA on a 
set of quality control metrics, which automatically identifies outliers based on the PCA components. 
Here, we used the number of unique features detected, library size, and the percentage of counts 
represented by the top 100 features (Figure 7.2B). Using the previous manual cut-offs, we discarded 
more cells than the automatic function of scater (Figure 7.2C), although all of the outliers captured by 
this function were also considered as such by the former manual method (Figure 7.2D).     
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Figure 7.2: Quality control of the Spaethling dataset. A -  Scatterplot of the percentage of mitochondrial genes vs the number 
of unique genes, coloured by cell type; B – PCA generated by the automatic outlier detecting function from the Scater package, 
coloured by the outliers detected using manual cut-offs and shaped by whether cells or considered to be outliers by the 
automatic function; C -   Scatterplot of the percentage of mitochondrial genes vs the number of unique genes, coloured by the 
outliers detected or not in the Scater function; D – Venn diagram of the outliers detected by the Scater function and by the 
manual cut-offs. 
 
After filtering low quality cells, we looked at the identities of the most highly expressed genes in the 
dataset (Figure 7.3). These are mostly constitutively expressed genes that encode for ribosomal and 
mitochondrial proteins. In the case of absence of ribosomal proteins or the presence of their 
pseudogenes, there could have been suboptimal alignment of the reads. 
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Figure 7.3: Percentage of total counts attributed to the top 50 most highly-expressed features in the Spaethling dataset. Each 
bar represents the percentage attributed to a feature for a cell, with the circle representing the average across all cells. Bars 
are coloured by the total number of expressed features in each cell and circles by whether the feature corresponds to a 
mitochondrial gene. 
 
To facilitate the downstream analysis by reducing noise and the number of features, we filtered lowly 
expressed features by considering a threshold of at least five reads in at least two cells (Figure 7.4), 
which resulted in 12,216 features excluded, out of 57,799.  
 
 
Figure 7.4: Number of expressing cells vs the log10-transformed mean expression for each feature in the Spaethling dataset, 
before (left) and after (right) filtering lowly expressed genes. Mitochondrial genes are highlighted in red. 
 
In order to visualize the dataset, we applied dimensionality reduction techniques, namely, PCA and t-
SNE, using the log-transformed count matrix (Figure 7.5A). In the PCA, the first component separated 
astrocytes and endothelial cells from microglia. Neurons and unidentified cells were scattered along this 
component, while the second component separated mostly astrocytes, neurons, and unidentified cells 
from microglia and endothelial cells. In the t-SNE, there were already clusters of cells being grouped by 
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cell type, although some neurons and unidentified cells remained relatively dispersed amongst other cell 
types. 
To identify possible confounding variables, we plotted the percentage of the variance of expression 
values that is explained by the set of known variables (7.5B). The percentage explained by the number 
of unique features detected was relatively low, approaching 1%. Library size had a bimodal distribution, 
with the higher peak at 1% and the lower one at 10%. Sequencing date accounted for about 10% of 
variance in the dataset. Given that this variable represents mostly technical artefacts, it was considered 
a target for batch effect normalization. However, there were 52 different sequencing dates from the year 
2013 to 2017, with most of the cells being sequenced in 2015. Therefore, we defined a new variable, 
date_groups, that consisted of joining the dates that comprised the minority of cells from different years 
into only one category.   
Subject and body site were confounded with cell type, knowing that some cell types belonged mostly to 
one subject, and most subjects had tissue extracted from only one part of the brain. The remaining 
variables did not appear to account for much variance in the dataset.  
 
 
Figure 7.5: A- PCA and t-SNE of the Spaethling dataset; B – Explanatory variables. 
 
After normalizing the dataset for library size and batch effect, the variance explained by variable 
date_groups notably decreased (Figures 7.6C and 7.6F). However, when looking at the t-SNE (Figures 
7.6A, 7.6B, 7.6D and 7.6E), there still appeared to be clustering of cells by proximate dates, e.g. neurons 
sequenced on 08/2015 clustering with astrocytes sequenced on 09/2015. To check if normalization for 
batch effect was effectively removing the technical component of gene expression, we performed 
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pairwise differential expression analysis between different cell types, using the raw count matrix (before 
normalization), and the log-transformed count matrix (after normalization for library size and batch 
effect). This analysis revealed that normalization introduced a bias where genes with higher expression 
showed a tendency to have a higher moderated T-statistic (Figure 7.7B). In addition, batch effect 
correction led to a group of genes with very low expression exhibiting aberrant values of moderated T-
statistic. Thus, we decided to continue the analysis without performing batch effect correction, given 
that it did not result in any advantage for this dataset, and tried to understand what were the drivers of 
proximity in the clustering analysis. 
 
 
 
Figure 7.6: Normalization and batch effect correction of the Spaethling dataset. A – t-SNE after normalization for library size, 
coloured by cell type; B – t-SNE after normalization for library size, coloured by the variable date_groups; C – Explanatory 
variables after normalization for library size; D – t-SNE after normalization for library size and correction of batch effect, 
coloured by cell type; E – t-SNE after normalization for library size and correction of batch effect, coloured by the variable 
date_groups; F - Explanatory variables after normalization for library size and batch effect correction;  
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Figure 7.7:Example of the results of performing pairwise differential expression analysis in the Spaethling dataset, without 
normalization, after normalization for library size (scran) and after normalization for library size and correction of batch effect 
(scran + limma). A – Volcano plots resultant of the comparison of astrocytes and endothelial cells; B – Scatter plot of 
moderated t-statistic vs mean gene expression for the astrocyte and endothelial cell comparison.  
 
7.1.2. Pseudotime analysis 
 
The t-SNE of the Spaethling dataset (Figures 7.6A, 7.6B, 7.6D and 7.6E) resembled a trajectory between 
unidentified cells, neurons and astrocytes (Supplementary figure 10.2). Given that cells sequenced in 
this dataset were submitted to long-term cell culture, this could mean that we were dealing with different 
stages of differentiation. Thus, we conducted a pseudotime analysis to check for an underlying 
developmental trajectory. The results indicate that there was indeed a trajectory, with a root composed 
of astrocytes, neurons and unidentified cells, followed by unidentified cells with intermediate 
pseudotime values and culminating in a cluster of mostly neurons and unidentified cells (Figure 7.8A). 
An alternative state of differentiation can be suggested, represented by microglia and endothelial cells. 
When plotting the t-SNE coloured by pseudotime score, we see a clear correspondence between the cells 
position and their pseudotime score (Figure 7.8B). 
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These results are in concordance with the original publication (Spaethling et al., 2017), in which 
astrocytes were described as being actively dividing, which meant they were less differentiated than the 
remaining cell types. Unidentified cells were not assigned a cell type due to having ambiguous 
morphology traits and marker genes that could correspond to either neuronal or glial cell types. We 
speculate these cells could also represent an undifferentiated cell type, such as radial glia, capable of 
generating both neurons and astrocytes (Barry, Pakan and McDermott 2014). It is also known that 
astrocytes are able to convert into neurons under specific conditions, so we can speculate that in a hostile 
environment, resembling a wounded brain, astrocytes may suffer a transition and develop into cells that 
have properties both similar to astrocytes and neurons (Cheng et al. 2015; Laywell et al. 2005).  
 
 
Figure 7.8: Pseudotime analysis of the Spaethling dataset. A – Visualization of the trajectory in the reduced dimensional space, 
coloured by cell type (left) and by pseudotime (right); B – t-SNE coloured by pseudotime (left) and by cell type (right).  
 
7.1.3. Feature selection and clustering  
 
In most scRNA-seq experiments, only a portion of genes show a response to the biological condition of 
interest, e.g., differences in cell-type. Feature selection is a useful step to remove genes which were only 
detected at different levels due to technical noise. This step is also important in increasing the 
computational efficiency of the analysis, by reducing the total amount of data necessary to process, e.g., 
in clustering methods.  
In this project, we tested two different methods, which consisted in the identification of highly variable 
genes (HVG) and high dropout genes (HDG).  Finding HVG consists on assuming that some genes have 
large differences in expression across cells due to biological variability, rather than technical noise, after 
correcting for the positive relationship between variance and mean expression. Finding HDG consists 
of identifying genes with unexpectedly high dropout rates. Dropout rates, as discussed in section 4.2, 
are related with average expression level, and result from a failure in mRNA reverse transcription. 
Because reverse transcription is an enzymatic reaction, it can be modelled using the Michaelis-Menten 
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equation. Using the HVG and HDG methods, we identified 2,351 and 6,932 features, respectively, with 
677 significant features in common between both methods (Fisher's Exact Test, p-value < 2.2e-16).  
 
Next, we performed consensus clustering to verify if cells clustered by cell type. We tested the use of 
all of the features captured in the dataset, the features selected with HDG, the features selected with 
HVG, and the features selected in common with both methods (Figure 7.9). We found that cells tended 
to cluster according to their cell type, although the astrocyte and microglia clusters also contained 
neurons. Endothelial cells have a different origin relative to neuronal and glia cells, and, therefore, 
formed very clean clusters. Instead of clustering with cells for which their type was known, unidentified 
cells consistently formed separated clusters, except for a few that clustered together with astrocytes and 
neurons.  
 
 
Figure 7.9:Consensus matrices of the Spaethling dataset, clustered based on log-transformed gene counts, using the whole set 
of available features (right top), using selected features with HDG or HVG (left top and bottom, respectively), and using 
common features between the latter methods. 
 
These results were consistent with the pseudotime analysis, in which a group of unidentified cells 
appeared to be in the same state as astrocytes, and the rest followed a trajectory to the end of the branch 
(Figure 7.10).   
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Figure 7.10:Consensus matrix of the Spaethling dataset, , clustered based on log-transformed gene counts , using only selected 
features with HDG. Pseudotime (state of differentiation) along with cell type seem to be the main drivers of cell similarity.  
 
Carrying out feature selection proved to be beneficial for the clustering analysis, obtaining cleaner 
clusters of cell types comparatively to performing clustering with the full set of genes (Figure 7.9 and 
7.10). The use of the common features, selected with both tested methods, generated the cleaner 
consensus matrix, with the majority of cells assigned to the same cluster after multiple clustering 
attempts using different parameters. This confirms the usefulness of feature selection methods in 
capturing relevant features, i.e., with variability in expression due to biological signal, thus reducing 
noise in the dataset.  
Before determining the neuronal and glia gene signature, it was important to obtain very pure clusters 
of cells types, considering the uncertainty in the preliminary cell type labelling. Therefore, we used the 
consensus clustering results to remove ambiguous cells, i.e., cells present in a cluster where the majority 
of cells were of a different type. We also put aside unidentified cells, as the majority of their identities 
were not clear at this stage.  
 
7.1.4. Marker genes 
 
In order to find marker genes for each population of different cell types, we tested different combinations 
of feature selection and classification methods. As expected, the number of defined marker genes varied 
not only when using different algorithms of classification, but also when using the same algorithm for 
classification and varying the feature selection method (Table 7.1). The classification algorithm applied 
in the SC3 function returned the lowest number of genes. However, the utilization of this function 
implies the application of user-selected cut-offs, for AUROC and p-value, which significantly affects 
the number of marker genes considered. 
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Table 7.1: Combination of feature selection and classification methods, to obtain the marker genes for each neural cell 
population.  The combination of HDG & HVG common genes and SC3 returned under 50 marker genes. Therefore, it was 
excluded from the analysis. 
 
 
We tested the resultant gene signatures with the cell type deconvolution tool, CIBERSORT, by using 
aggregated pseudobulk data, which consisted of summing count measurements from different 
proportions of cell types (Figure 7.11). In general, all of the combinations of methods generated gene 
signatures capable of estimating the gross relative abundances of each cell type. The gene signature from 
combination 1, in particular, demonstrated a relatively high level of concordance in this task, which was 
expected, given that it had the higher number of genes.  
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Figure 7.11: Results of performing cell type deconvolution on pseudobulk data, using gene signatures that resulted from each 
of the combinations of methods used. Each bar plot contains pairs of bars representing the expected scores for each cell type 
(T) and the scores obtained using the deconvolution tool (C). The combination, as in Table 7.1, used to obtain the gene signature 
is identified on top of each plot. 
 
To ascertain whether these gene signatures were capable of generalizing the discrimination of the major 
brain cell types in external datasets, we tested them for their ability to correctly classify neurons, 
astrocytes and microglia cells from the scRNA-seq Darmanis dataset, using CIBERSORT. 
Combination 1 generated the only gene signature capable of classifying neurons (Figure 7.12). However, 
this combination failed to classify astrocytes, as did the remaining combinations (Figure 7.13). Although 
combination 5 and 7 exhibited less noise in the classification of astrocytes comparatively to the 
remaining methods, they also incorrectly classified most neurons as being mostly astrocyte-like, which 
could indicate the existence of overfitting, i.e., the model was incorrectly optimized for astrocytes, 
resulting in the elevated number of false positives. Notably, combination 5 using the SC3 function 
generated a gene signature with 71 genes that did not perform worse than the gene signature with 2344 
genes obtained using combination 7 with elastic nets. Furthermore, microglia in general appeared to be 
an easier cell type to properly classify in an external dataset (Figure 7.14). These results were expected, 
given that microglia arise from a different progenitor than that of the remaining glia cell types, while 
astrocytes and neurons can share a common progenitor from which they differentiate. Hence, microglia 
cells likely have a gene expression profile more dissimilar to astrocytes and neurons.   
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Figure 7.12: Results from performing cell type deconvolution with gene signatures generated by combinations of methods 1 to 
8. This analysis was performed only on neurons from the Darmanis dataset. 
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Figure 7.13:Results from performing cell type deconvolution with gene signatures generated by combinations of methods 1 to 
8. This analysis was performed only on astrocytes from the Darmanis dataset. 
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Figure 7.14: Results from performing cell type deconvolution with gene signatures generated by combinations of methods 1 to 
8. This analysis was performed only on microglia from the Darmanis dataset. 
 
Summarizing, the SC3 method is useful in reducing the number of marker genes, without extensively 
compromising the accuracy of cell type deconvolution in pseudobulk data. Considering that all the gene 
signatures under-performed in the generalization task with the external dataset, we hypothesized this 
was due to variability in gene expression resulting from one dataset having cells acutely removed from 
the brain environment (Darmanis) and the other cultured before sequencing (Spaethling). In order to 
further explore this hypothesis, and to obtain a gene signature that captured the common gene expression 
profile between cells of the same type and of different states, we decided to continue the analysis by 
merging the two datasets. 
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7.1.5. Merging scRNA-seq datasets 
 
In order to merge the Spaethling and Darmanis datasets, we decided to exclude endothelial cells from 
the analysis, given that the latter dataset did not include this cell type and also taking into consideration 
that endothelial cells were expected to comprise only a very small proportion of brain tissue. 
After combining both datasets, there was a clear grouping on the t-SNE based on the dataset of origin 
(Figures 7.15A - 7.15F). The Darmanis dataset also had smaller library sizes, which was expected given 
the different sorting and sequencing protocols. After normalization, the differences in library sizes were 
corrected but the cells remained clustered by dataset. Hence, we performed batch correction, after which 
cells clustered based on their cell type, with sub-clustering occurring to some extent between within 
cells of the same type and of the same dataset of origin. 
 
 
Figure 7.15: t-SNEs of the merged Spaethling and Darmanis dataset, before normalization (A,D), after normalization for 
library size (B, E), and after normalization for batch effect (C, F). Plots are coloured by cell type (left) and by original dataset 
(right). 
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Although this correction approximated astrocytes, they still formed two very distinct clusters based on 
the original dataset. We considered that this could be due to not only technical noise but also biological 
variability, since isolated cells from the Spaethling dataset were cultured up to 84 days in vitro before 
sequencing, and astrocytes were described as being actively dividing, contrasting with astrocytes from 
the Darmanis dataset, which were acutely isolated and sequenced. It is known that cultured astrocytes 
develop a reactive phenotype, as if their environment was disrupted in the case of brain lesion 
(Schiweck, Eickholt, and Murk 2018; Liddelow and Barres 2017). In addition, after normalizing for 
batch effect, the variance explained by the original dataset was significantly reduced, from reaching over 
10% to about 0.01% (Figures 7.16A – 7.1C).  
 
 
Figure 7.16: Explanatory variables of the Spaethling and Darmanis merged dataset, before normalization (A), after 
normalization for library size (B), and after normalization for batch effect (C). The plotted variables correspond to the number 
of unique genes detected (total_features_by_counts), library size (total_counts), cell type and dataset of origin. 
 
To confirm that the existence of two different groups of astrocytes was due to biological variability, we 
used the SC3 function to obtain the top 100 marker genes for each group of astrocytes and performed 
Gene Ontology (GO) enrichment analysis. As hypothesized, GO annotations for the Spaethling astrocyte 
marker genes were mostly associated with a reactive phenotype, e.g., astrocyte activation and 
neuroinflammatory response (Supplementary table 10.1). On the other hand, Darmanis astrocytes’ 
annotations were related with the astrocytic role in controlling the levels and activity of several 
neurotransmitters, e.g., L-glutamate and D-aspartate import across plasma membrane (Supplementary 
table 10.2). Because these represent two different states of astrocytes, we decided to keep them as 
separate cell sub-types in the downstream analysis.  
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7.1.6. Gene signature for brain cell types 
 
To obtain the final gene signature of the major cell types of the brain, we performed HDG feature 
selection on the merged dataset, which returned 7,662 selected features. Following, we tested both 
PAMR and the SC3 function, resulting in 2321 and 1126 features, respectively. Validation of these 
signatures was performed using a train/test split of the dataset balanced by cell type and dataset of origin, 
i.e., we used the train dataset (266 cells) to obtain the marker genes, and validated the gene signature by 
performing cell type deconvolution on the test dataset (173 cells). Considering that both signatures were 
able to properly classify neurons, astrocytes, microglia and oligodendrocytes in the test dataset, we 
looked for marker genes common to both approaches, to diminish the number of necessary features. 
This returned our final gene signature, with 889 significant common marker genes (Fisher's Exact Test, 
p-value < 2.2e-16).  
Finally, to confirm that the gene signature was able to be generalized to external datasets, we performed 
cell type deconvolution on the scRNA-seq Zhang dataset (Figure 7.17). We were able to properly 
classify human and mouse astrocytes, considering the astrocyte score as the sum of scores from different 
astrocyte states. Although there was some overlap between astrocyte marker genes of different states, 
astrocytes from the Zhang dataset were more similar to astrocytes from the Darmanis dataset, as 
expected, given that the latter were also acutely removed and sequenced.  
Furthermore, neurons and microglia were also correctly classified. However, this method failed to 
correctly classify oligodendrocytes, with only 2 out of 5 showing a score over 0.5 for the 
oligodendrocyte cell type. This may be due to the fact that oligodendrocytes are difficult to isolate and 
may contain myelin and axon debris (Pfenninger et al. 2007; Tham et al. 2003). 
 
 
 
Figure 7.17:Results of cell type deconvolution on the Zhang dataset, with the final gene signature. 
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7.2. Unveiling how the relative abundance of neurons and glia in the brain correlates 
with ageing and neurological health 
 
The following analysis consisted of using the previously defined and validated neuronal and glia gene 
signature to perform cell type deconvolution of publicly available bulk RNA-sequencing datasets of 
AD, PD and non-AD-PD brain tissues. 
 
7.2.1. Cell type deconvolution of the healthy brain 
 
We performed neural cell type deconvolution of bulk RNA-seq datasets of non-diseased brain tissue, 
available from GTEx.  We started by looking at the whole set of brain tissues available, distributed 
among amygdala, anterior cingulate cortex, caudate (basal ganglia), cerebellar hemisphere, cerebellum, 
cortex, frontal cortex, hippocampus, hypothalamus, nucleus accumbens (basal ganglia), putamen (basal 
ganglia), spinal cord (cervical c-1), and substantia nigra. Next, we selected specific neural tissues to 
explore in further detail, namely cortex, frontal cortex, anterior cingulate cortex, cerebellar hemisphere, 
hippocampus, substantia nigra, and spinal cord.  
When considering the analysis performed on the total set of available tissues, the most abundant cell 
type was neuron, followed by astrocyte, oligodendrocyte and microglia (Figure 7.18). These proportions 
are only representative of the amount of mRNA in each cell type. Currently, there is still no method to 
convert these values into true cell proportions. However, there is a correlation between the amount of 
mRNA and the number of a given cell type, which is useful for the analysis intended in this work. 
Taking the above into consideration, we found that the relative proportions of neural cell types may vary 
extensively, depending on the region of the brain that is being analysed. For example, there were tissues 
with a relatively high median of the relative proportion of neurons, namely cortex (0.7234), cerebellar 
hemisphere (0.8723), and frontal cortex (0.7694), in contrast with substantia nigra (0.5195), 
hippocampus (0.6201) and spinal cord (0.2577). The proportion of astrocytes did not show as much 
variability as the proportion of neurons, albeit the cerebellar hemisphere showing a relatively lower 
median than the rest of the tissues (0.11812). Most tissues presented a very low proportion of 
oligodendrocytes, with exception of the spinal cord, followed by the hippocampus and substantia nigra, 
although the two latter had lower median values (0.41219, 0.09933 and 0.144677, respectively). The 
same occurred for microglia, with the spinal cord and substantia nigra presenting the higher median 
values (0.08074 and 0.01383, respectively), although the relative abundance of this glia cell type was, 
in general, very low in every tissue.  
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Figure 7.18: Box plots of age and relative proportions of brain cell types, grouped by brain tissue. TBS – Total brain samples; 
ACC – Anterior cingulate cortex; C – Cortex; CH – Cerebellar hemisphere; FC – Frontal cortex; H – Hippocampus; SC – 
Spinal cord; SN – Substantia nigra. 
 
We further investigated whether there was a correlation between the relative proportion of each cell type 
and age, for each of the brain tissues selected (Table 7.2). With exception of the cerebellar hemisphere, 
every tissue showed a significant negative correlation between the relative proportion of neurons and 
age, and a concomitant increase in one or several types of glia cells.  
Regarding the cerebellar hemisphere, as mentioned in the previous analysis, this tissue presented a 
higher relative proportion of neurons comparatively to other brain tissues, and, therefore, the variation 
of neuronal relative proportions with ageing in this tissue might not be enough to be captured using this 
method. However, it was also the only tissue that exhibited a negative correlation between the relative 
proportion of oligodendrocytes and ageing, which could be an indicator of the occurrence of 
demyelination with ageing in the cerebellar hemisphere (Adamo, 2013). 
45 
 
Table 7.2: Results of the Spearman’s correlation analysis between the relative proportions of brain cell types in each analysed 
tissue and age. Green and red rows highlight significant (p < 0.05) and possible meaningful positive and negative correlations, 
respectively. 
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7.2.2. Cell type deconvolution of the brain in Alzheimer’s disease 
 
To ascertain whether there was an alteration in the relative proportions of the major cell types in the 
brain of AD patients, we performed cell type deconvolution in a bulk RNA-sequencing dataset of post-
mortem fusiform gyrus of AD patients and non-AD samples. According to the previous analysis, there 
is a tendency for a decreased neuron proportion, concomitant with an increase in glia cell proportion, 
with ageing, in the cerebral cortex. In accordance with previous findings (Mukhin, Pavlov and Klimenko 
2017), this shift is accentuated in AD brain relative to non-AD brains. The latter were, in general, older 
than AD patients, allowing us to rule out age as a possible confounding factor (Figure 7.19).  
 
 
Figure 7.19:Box plots of age and relative proportions of brain cell types, in Alzheimer’s disease affected fusiform gyrus and 
healthy fusiform gyrus (control).  
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7.2.3. Cell type deconvolution of the brain in Parkinson’s disease 
 
PD has been previously associated with a decrease in the number of neurons in the brain, particularly 
dopaminergic neurons in the substantia nigra pars compacta. However, symptoms such as tremors and 
dementia indicate the occurrence of progressive neurodegeneration in the cerebral cortex in PD brain, 
which is accentuated in later stages of the disease (Cechetto and Jog 2017; Yau et al. 2018). 
The following analysis consisted on performing cell type deconvolution in a bulk RNA-sequencing 
dataset of post-mortem frontal cortex brain tissue, of PD and non-PD samples. Although the shift in the 
proportion of neurons in this dataset is not as pronounced as in the AD analysis, there is also a decrease 
in the proportion of neurons in PD frontal cortex relative to non-PD samples, concomitant with an 
increase in the proportion of astrocytes (Figure 7.20). 
 
 
Figure 7.20: Box plots of age and relative proportions of brain cell types, in Parkinson’s disease affected frontal cortex and 
healthy frontal cortex (control). 
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7.2.4. Immune cell type deconvolution of the healthy brain 
 
For many years the CNS has been considered to be immune privileged, having physical barriers that 
prevent the entry of blood components, such as leucocytes (Loeveau, Harris and Kipnis 2015). However, 
it is known that immune cells have important roles in the development, maintenance and repair of the 
brain. There have been studies showing that although the healthy brain is constituted by about 10% 
microglia, there is still a need for macrophages to enter and aid in the case of a brain lesion (Tanabe and 
Yamashita 2018; Shechter et al. 2013). 
CD4+ T cells have been described as being key regulators of this monocyte-derived macrophage entry 
in the CNS, by remotely producing pro-inflammatory cytokines that activate the production of cell-
adhesion molecules in the blood-cerebrospinal-fluid (CSF) barrier (Kunis et al. 2013).  However, with 
ageing, there is an increase in the permeability of the BBB, which allows the pathological entry of 
leucocytes in the CNS (Yamazaki and Kanekiyo 2017). Thus, there is a reduction in the number of T 
cells, which leads to under-activation of the CSF-barrier, preventing macrophages from entering the 
brain and removing toxic accumulating plaques (Kunis et al. 2013).  
In order to investigate whether the brain is indeed immune privileged, or if there are infiltrating immune 
cells in the brain, we performed immune cell type deconvolution of bulk RNA-seq datasets of healthy 
brain tissue, available from GTEx (The GTEx Consortium, 2013), using the whole set of brain tissues 
available. Given that immune cells do not comprise the major part of cell types in the brain, the analysis 
focused on studying the absolute levels of immune cells, rather than the relative proportion, using the 
previously validated immune cell type signature LM22.   
The results suggested that the brain is not depleted from immune cells, besides microglia (Figure 7.21). 
Resting CD4+ memory T cells presented the highest absolute scores, with a relatively high level of 
variability between individuals. Although T cells have been previously described in the human brain 
parenchyma, they were found to be mostly memory CD8+ T cells, while memory CD4+ T cells are rarer 
(Smolders et al. 2018). However, an increase in the transmigration of CD4+ T cells in the CNS has been 
previously reported in brains affected by AD and PD, comparatively to brains from controls without 
neurological disease (Gemechu and Bentivoglio 2012). All of the above considered, there is still a need 
to pursue a systematic analysis of T cell infiltration in the non-diseased human brain at different ages, 
versus brains affected by neurodegenerative disease (Gemechu and Bentivoglio 2012). 
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Figure 7.21: Box plots of relative proportions of immune cell types in the non-diseased brain. 
 
7.3. Evaluating the cellular diversity and molecular signature of TAMs 
 
7.3.1. Normalization and clustering 
 
In the following analysis, we aimed at exploring breast tumour-infiltrating macrophage diversity, using 
the scRNA-seq Azizi dataset. 
Prior to normalization, we plotted the percentage of variance of the expression values that was explained 
by library size (total_counts), number of unique features detected (total_features_by_counts), patient, 
replicate and original cell type labelling (azizi_cell_type). The percentages explained by library size and 
the number of unique features detected were relatively high, approaching 10% (Figure 7.22A), 
indicating that there were technical confounding factors. Plotting the same variables after normalization, 
the percentage of variance explained by these variables was significantly reduced (Figure 7.22B), 
demonstrating the successful removal of biases originated during the library preparation and sequencing 
process.  
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Figure 7.22: Density plots of the percentage of variance explained of the log-expression values across cells.  Each curve 
represents one variable before normalization (A) and after normalization (B). 
 
Plotting the t-SNE coloured by original cell type labelling (Figure 7.23A), and patient (Figure 7.23B), 
we confirm that cells primarily cluster by cell type. Although there were cell types for which the majority 
of cells came from only one or two patients, such as natural killer T cells and macrophages, cells that 
originated from several different patients, e.g., B cells and mast cells, were clustering by cell type.  
Hence, we decided not to perform patient-batch effect correction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.23: t-SNE of the Azizi dataset, coloured by cell type (A) and patient (B). 
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Next, we performed clustering analysis, to check if the clusters obtained were concordant with cell type. 
Plotting the t-SNE coloured by the resulting clusters (Figure 7.24B), there were clear groups composed 
of mainly one cell type, e.g. B cells, mast cells and neutrophils. In general, there was a relatively high 
concordance between the t-SNE clusters, clusters obtained from the clustering tool, and cell types. The 
level of concordance between cell types and clusters defined by the Seurat function was summarized in 
a confusion matrix (Figure 7.24A). For some cell types, there were very homogeneous clusters where 
the majority of cells belonged to the same type, e.g. neutrophils and mast cells. However, monocytes, 
together with monocyte precursors, and mDCs, were not easily separated by cell type based solely on 
gene expression, which is likely depicting the lineage relationship between these cell types, together 
with macrophages. Hence, there is a likely continuum between these cells rather than discrete groups.  
 
 
Figure 7.24: Results from the clustering analysis of breast tumour-infiltrating immune cells. A – Confusion matrix showing 
the percentage of each cell type per cluster. B – t-SNE coloured by cluster.  
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7.3.2. Identifying macrophage subpopulations 
 
In order to explore the diversity of TAMs, we isolated the macrophages and performed clustering 
analysis on this subset. We obtained 3 clusters, two from the same patient (BC6) and one from a different 
patient (BC8) (Figures 7.25A and 7.5B).  
 
 
 
Figure 7.25: t-SNEs of the Azizi dataset, coloured by the results of clustering (A) and by patient (B). 
 
Next, we performed differential expression analysis to identify different macrophage polarizations based 
on the clusters previously obtained. By comparing each of the clusters to the remaining, we obtained 
200 upregulated genes in cluster 0, 289 upregulated genes in cluster 1 and 179 upregulated genes in 
cluster 2 (average logFC > 0.25 and corrected p-value < 0.05).  
Considering the top 10 differentially expressed genes of each cluster (ordered by increasing corrected 
p-value) (Figure 7.26A), cluster 0 presented genes related with intracellular storage of iron, namely FTL 
(Ferritin Light Chain) and FTH1 (Ferritin Heavy Chain 1). It is known that macrophages have a pivotal 
role in iron homeostasis, and that macrophage polarization towards iron sequestration fosters 
inflammation, in contrast with iron release, which contributes to tissue repair and cell proliferation 
(Mertens et al. 2016). FTL has been previously reported to be upregulated in M1 macrophages, 
comparatively to M2 macrophages (Mertens et al. 2016).  
There were also genes involved in the phagolysosome system, namely CSTB (Cystatin B) and CTSD 
(Cathepsin D). CSTB codes for a protein that protects against cathepsins that leak out of lysosomes. 
CSTD is a cathepsin, i.e., a protease that degrades proteins and activates precursors of other bioactive 
proteins in the lysosome. This enzyme is highly abundant in macrophage lysosomes. The upregulation 
of this gene could be indicative of a high level of phagocytosis (Bewley et al. 2011), which is associated 
with M1 phenotype (Atri, Guerfali and Laouini 2018; Weagel et al., 2015). Furthermore, CSTB has 
been previously reported to be expressed in mouse M1 macrophages, under specific stimulating 
conditions (Torre-Minguela et al. 2016). Interestingly, cystatins have also been shown to induce 
production of nitric oxide (NO) in mouse macrophages (Luciano-Montalvo and Meléndez, 2009; Verdot 
et al. 1996), which, together with the production of ROS, is a hallmark of the M1-phenotype (Atri, 
Guerfali and Laouini 2018; Weagel et al., 2015). Another upregulated gene in this cluster was ACP5 
(acid phosphatase 5, tartrate resistant), an enzyme that is highly expressed by activated macrophages. 
Although its function remains unclear, it has been proposed to be involved in the generation of ROS and 
increased bacterial killing in macrophages (Räisänen et al. 2005).  
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On the other hand, cluster 2 presented upregulated genes that have been described in the M2-phenotype, 
e.g., SEPP1 (Chinetti-Gbaguidi and Staels 2011). Although not present in the top 10, two known M2 
macrophage canonical markers were also significantly upregulated in this cluster, MRC1 (CD206) 
(Martinez and Gordon 2014) and CD209 (Lugo-Villarino et al. 2018).  While cluster 0 presented genes 
associated with iron sequestration, macrophages from cluster 2 presented upregulated expression of 
SLC40A1, a gene that codes for the Ferroportin protein, the only known iron exporter. This iron-release 
macrophage M2-like phenotype has been previously described (Mertens et al. 2016), and is an active 
topic of research, considering that the presence of iron in the microenvironment stimulates tumour 
growth and progression. Thus, applying macrophage-targeted chelation strategies might prevent tumour 
progression, posing new possibilities in the treatment of cancer (Mertens et al. 2016). Another 
interesting upregulated gene is LYVE1, which codes for a cell surface receptor usually expressed on 
lymphatic endothelial cells. There have been studies linking this gene to the role of M2 macrophages in 
lymphangiogenesis (Corliss et al. 2016), although in the context of cancer, one study reported an 
association between LYVE1-expressing M2 macrophages and inhibition of melanoma cell proliferation 
(Dollt et al. 2017). Cluster 2 also expressed genes related with the classical complement pathway, C1QC 
and C1QA. In the context of macrophage polarization, C1Q has been described as being overexpressed 
in M2 macrophages (Fraser et al. 2015).  
Finally, cluster 1 analysis did not result in marker genes characteristic of the traditional M1/M2 
macrophage classification, being particularly enriched in genes that code for MHC (major 
histocompatibility complex) class II and ribosomal proteins. To see if these macrophages were more 
similar to cluster 0 (M1-like) or cluster 2 (M2-like), we performed differential expression analysis 
comparing only cluster 0 and 2, and plotted the heatmap of the top 10 differentially  expressed genes, in 
order to verify if cluster 1 presented a gene expression profile more similar to either one of these clusters 
(Figure 7.26B).  The expression profile of cluster 1 did not seem to resemble neither cluster 0 or cluster 
2, ascertaining it as a different phenotype, possibly more transcriptionally active than the remaining.  
 
 
Figure 7.26: Heatmaps representing the top 10 differentially expressed genes of each cluster from the differential expression 
analysis between cluster 0, 1 and 2 (A), and between cluster 0 and 2 (B). 
 
In summary, this analysis, together with growing information indicating that recognition receptors, 
cytokines, and the signalling and genetic programs are all factors that influence macrophage 
polarization, emphasizes the need to recognize a broader functional repertoire for macrophages 
(Martinez and Gordon 2014). There is also a necessity to carefully determine the effect of particular 
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TAM subpopulations on tumour progression, before establishing a treatment to target these immune 
cells (Dollt et al. 2017). 
 
7.4. Understanding how the intra-tumoural diversity and functionality of infiltrating 
immune cell types is associated with age and prognosis 
 
7.4.1. Deconvolution of immune cell types of TCGA samples 
 
Using the previously validated immune gene signature LM22 (Chen et al. 2018), we performed immune 
cell type deconvolution of over 800 bulk RNA-seq samples of breast tumour.  
By looking at the averages of the relative abundances of each major immune cell type, we confirm that 
these are in accordance with what is expected from the literature (Cassetta and Pollard 2018), namely 
macrophages representing the major tumour-infiltrating population, followed by T and B cells (Figures 
7.27A and 7.27B). When grouping samples by patient age range, we observe an increase in pro-
tumourigenic (M2) macrophages with age, and also a subtle decrease of infiltrating CD8+ T cells 
(Figures 7.27C and 7.27D). The correlation between age and the increase in the relative abundance of 
tumour-infiltrating M2 macrophages was significant (Spearman’s correlation coefficient, p-value < 
0.0001), albeit the correlation coefficient being low (rho = 0.14). Regarding the association between the 
relative abundance of CD8+ T cells with age, the correlation was not significant at a level of 0.05 (p-
value = 0.07 and rho = -0.066) (Figure 7.28). Nevertheless, considering the dimension of the dataset, 
and the fact that we would not expect dramatic shifts in the proportion of immune cells with ageing, the 
observed differences could still be worth exploring in future work.   
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Figure 7.27: Analysis of cellular composition deconvolution of TCGA breast cancer RNA-seq samples. A - Average immune 
cell composition obtained from the literature, expressed as estimated fractions of leukocyte RNA, in bladder, breast, bowel, 
stomach and lung cancers. Adapted from Cassetta and Pollard 2018. B – Average proportion of immune cell types in breast 
cancer, obtained from our preliminary analysis. C – Average proportion of pro-tumour (M2) macrophages and CD8+ T cells 
in breast cancer, discriminated by age range. D – Box-plots showing the distribution of the fraction of pro-tumour macrophages 
and CD8+ T cells discriminated by age range. 
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Figure 
7.28: Scatter plots of the relative proportion of M2 macrophages vs age (A) and the relative proportion of CD8+ T cells vs age 
(B). Correlation was assessed using Spearman's Rank-Order Correlation test.  
We also found that the relative abundance of CD8+ T cells negatively correlates with the relative 
abundance of M2 macrophages (rho = -0.3, p-value < 2.2e-16). There is also a positive correlation 
between the relative abundance of CD8+ T cells and M1 macrophages (rho = 0.39, p-value < 2.2e-16), 
and a negative correlation between the relative abundance of M1 and M2 macrophages (rho = -0.43, p-
value < 2.2e-16). However, given that macrophages comprised the major part of breast tumour-
infiltrating immune cells, the decrease in the relative abundance of CD8+ T cells might be biased, i.e., 
when one population increases, there must be a relative decrease in other immune cell populations. 
We performed survival analysis to check if the tumour burden was associated with CD8+ T cell and M2 
macrophage relative abundances, finding that a high proportion of M2 macrophages was significantly 
associated with worse prognosis (p < 0.0001, log-rank test), while a high proportion of CD8+ T cells 
was significantly associated with better prognosis (p = 0.002, log-rank test) (Figure 7.29). 
 
 
Figure 7.29: Kaplan-Meier plots for patient stratification based on the relative proportion of M2 macrophages (left) and the 
relative proportion of CD8+ T cells (right).  
 
7.4.2. Differential expression and Gene Set Enrichment analysis 
 
In order to identify cellular pathways strongly associated with differences in the relative proportion of 
CD8+ T cells and M2 macrophages, possibly related with phenotypical changes in the breast tumour 
mass, we performed differential expression between two groups of tumours: those with relatively high 
proportion of CD8+ T cells and low proportion of M2 macrophages, and those with relatively high 
proportion of M2 macrophages and low proportion of CD8+ T cells. This resulted in 434 upregulated 
and 450 downregulated genes in the group of samples with relatively high proportion of CD8+T cells 
57 
 
and low proportion of M2 macrophages, after excluding marker genes belonging to the gene signature 
applied in the deconvolution analysis. 
We highlighted in red 3 genes of each category in the volcano plot (HLA.DOB, BCL11A and C4orf7 in 
the upregulated group of genes, and CLEC5A, MMP3 and METTL11B in the downregulated group), 
which presented a high B-statistic value together with a high log fold-change (Figure 7.30).  
 
 
Figure 7.30: Volcano plot showing the results of linear regression analysis comparing the groups of samples with relatively 
high proportion of CD8+ T cells and low proportion of M2 macrophages vs samples with relatively low proportion of CD8+ 
T cells and M2 macrophages. Genes were highlighted based on log fold-change values (logfolds) and B-statistic (b_statistic), 
except for C4orf7, considered an interesting outlier based on a high log fold-change value. 
 
C4orf7, renamed as follicular dendritic cell secreted protein (FDCSP), is expressed by follicular 
dendritic cells and activated leukocytes in the tonsils during immune responses. Interestingly, it has been 
described as having weak or no expression in peripheral blood leukocytes, spleen and bone marrow 
(OMIM Entry - * 607241 2019). The FCCSP secreted peptide is known to bind to B cells, and this 
process is enhanced by T cell-dependent activation signals, albeit the molecular basis for follicular 
dendritic cell and B cell interactions remains poorly characterized (Marshall et al. 2002). FDCSP has 
been found to have a high level of expression in some cancers, including breast carcinoma, and is 
thought to contribute to tumour metastases by promoting cancer cell migration and invasion. However, 
in the context of cancer, it appears to be expressed not by immune, but possibly cancer cells (Wang et 
al. 2010).  
BCL11A codes for a transcription factor highly expressed in the brain, B-lymphocytes, pDCs and the 
adult erythroid lineage (OMIM Entry - * 606557 2019; Ippolito et al. 2014). The BCL11A transcription 
factor is required for B cell and pDC development (Lee et al. 2017). It also appears to be related with 
NK and T cell development, but not with the myeloid compartment (Yu et al. 2012). Regarding cancer, 
BCL11A has been reported to be overexpressed in TNBC and have a role in the expression of expression 
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of extracellular matrix genes and in promoting tumour development and metastatic progression (Khaled 
et al. 2015; Seachrist 2018).  
HLA-DOB codes for a protein belonging to the class II major histocompatibility complex (MHC) 
molecules, and is expressed in APCs, namely, B cells, DC and macrophages (Ncbi.nlm.nih.gov 2019). 
IFN-γ signalling may also induce expression of MHC-II in tumour cells, and it has been reported that 
high MHC-II expression in TNBC is associated with larger amounts of TILs, and with better disease-
free survival in patients who had lymph node metastasis (Park et al. 2017). 
MMP13 codes for an enzyme produced predominantly by connective tissue cells. It is involved in the 
degradation of the major components of the extracellular matrix (OMIM Entry - * 600108 2019). Matrix 
metalloproteinases are major factors involved in the development of the tumour microenvironment, 
cancer progression and metastasis. MMP13 in particular has been described as being highly 
overexpressed in breast cancer tissue, with a potential role in breast cancer metastasis (Chang et at. 2009; 
Kotepui et al. 2016). 
CLEC5A codes for a cell surface receptor that is strongly involved in the activation and differentiation 
of myeloid cells, namely macrophages and neutrophils. Being associated with mature stages of myeloid 
differentiation, CLEC5A is expressed constitutively at very low levels, and is highly increased in 
activated macrophages during infection (Batliner et al. 2011).  
METTL11B codes for an enzyme that catalyses the methylation of proteins, e.g. histone proteins of 
chromatin, regulating gene transcription (Copeland 2018). These enzymes may also be involved in the 
methylation of non-histone proteins, with a role in cancer development and progression (Copeland 2018; 
Hamamoto and Nakamura 2016). 
In summary, the preliminary investigation of a small subset of significantly differentially expressed 
genes showed an association of adaptive immune cell activation with the high CD8+ T cell/ low M2 
macrophage group, and activation of myeloid cells in the low CD8+ T cell/ high M2 macrophage group.   
Next, we focused our analysis on the changes of expression in groups of biologically related genes by 
performing GSEA. The significant results (FDR < 0.1) of this method are summarized in table 7.3.  
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Table 7.3: MSigDB’s Hallmark Gene Sets (FDR < 0.1). 
 
One of the most significant hallmarks obtained for the high CD8+ T cell/ low M2 macrophage group 
was allograft rejection. Allograft rejection consists of an elicited response of the adaptive immune 
system to a donor tissue, in which T cells react to allogeneic MHC molecules expressed on the surface 
of donor cells. The emergence of this hallmark may be related with the immune system recognizing 
tumour antigens as nonself, which would elicit a cytotoxic T-cell attack on tumour cells (Genome.jp. 
2019). The remaining hallmarks were related with the production of pro-inflammatory cytokines. IFN-
γ, in particular, is secreted by NK and T cells upon activation of antigen-specific immunity. In the 
tumour microenvironment, this cytokine is associated with anti-proliferative, pro-apoptotic and anti-
tumour mechanisms (Boehm et al. 1997).   
Regarding the low CD8+ T cell/ high M2 macrophage group, the most significant hallmark was 
epithelial-mesenchymal transition, a process through which cells lose adhesion and gain migratory 
capacities. This mechanism is involved in tumour progression with metastatic expansion (Roche 2018). 
Another significant hallmark was TGF-β signalling, a cytokine previously implicated in the polarization 
of macrophages towards the M2-phenotype (Zhang et al. 2016). TGF-β also converts effector T-cells, 
which normally attack tumour cells, into regulatory (suppressor) T-cells, which turn off the 
inflammatory reaction (Dahmani and Delisle 2018). These results are concordant with the hypothesis 
that macrophage polarization is determined by microenvironment stimuli, M2 macrophages can affect 
malignancy progression and metastasis, and are involved in immune suppression (Weagel et al., 2015). 
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8. Concluding remarks 
 
Human bodies are frequently said to have 210 different types of cells (Trapnell, 2015). However, a 
single cell type can be divided by functional differences and subcategorized by unique gene expression 
programs (Trapnell, 2015). Advances in scRNA-seq technologies have revealed different gene 
expression profiles between cells once categorized as the same type, calling into question how we define 
cell type in the first place (Gage, Linker and Bedrosian, 2019). 
Wagner’s group defined cell identity as the outcome of the instantaneous intersection of all factors that 
affect it (Wagner, Regev and Yosef, 2016). Type is the permanent aspect of a cell, and states arise 
transiently during time-dependent processes, such as the cell cycle (Wagner, Regev and Yosef, 2016). 
Therefore, we can think of marker genes as the set of genes that are similarly expressed across all cells 
with identical function and that are consistent across all states (Gage, Linker and Bedrosian, 2019). 
Traditional approaches to cell type identification were based on morphological characterization, and/or 
identifying the presence of a small set of known markers. scRNA-seq methods, on the other hand, enable 
cell type classification with little or no prior knowledge, possibly revealing previously unidentified 
variations in cellular phenotypes across numerous tissue types (Gage, Linker and Bedrosian, 2019).  In 
this way, scRNA-seq provides a conceptual framework by which to assess cell type (Gage, Linker and 
Bedrosian, 2019). 
Rapid progress in the development of scRNA-seq protocols and computational methods in recent years 
has provided many valuable insights into the diversity of the immune system, in health and disease 
(Stubbington et al. 2017).  
In this work, we focused on implementing scRNA-seq data analysis approaches to unravel the role of 
the immune response in ageing-related human diseases, namely neurodegenerative and oncological 
ones.  
The characterization of gene expression signatures of the major cell types of the brain enabled the 
estimation of relative proportions of neurons and glia cells in brain tissue. This allowed us to look at the 
differences in these proportions across different CNS areas, as well as assess the correlation between 
neuronal loss and glial proliferation in brain tissue and ageing, and the accentuation of this phenomena 
in AD and PD.  
The use of scRNA-seq has also transformed cancer research by enabling the estimation of immune cell 
content in tumour tissues and the profiling of gene expression for tumour-infiltrating immune cells. In 
this work, focusing on breast cancer, we performed an inspection of the tumour microenvironment and 
its consequences for prognosis. We estimated the relative abundances of tumour-infiltrating immune 
cell types and how they correlated with age. Furthermore, we ascertained how the variability of tumour-
infiltrating macrophage and T cell patterns is associated with either induced immune suppression, or 
increased immunosurveillance in the tumour microenvironment.  
Finally, the immune system comprises a variety of immune cells, not only of multiple cell types, but 
also of different states within a cell type. Characterizing this complexity requires studies at the single-
cell resolution. Focusing on TAMs, due to their variety of microenvironment stimuli-dependent 
polarizations, we were able to characterize different activation states in the breast TME, which 
encompassed classically activated macrophages (M1), alternatively activated macrophages (M2) and a 
transcriptionally activated subtype of macrophage, not previously identified to the extent of our 
knowledge.   
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8.1. Analysis limitations 
 
Single-cell transcriptomics is a relatively new and still growing field. Hence, a gold standard for a 
scRNA-seq data analysis pipeline is yet to come. Taking this into consideration, during this work we 
tested different combinations of methods to perform feature selection and obtain cell type marker genes. 
Although some methods exhibited significant overlapping results, different methods usually resulted in 
different gene signatures, which led to different cell type deconvolution scores for the same dataset. This 
emphasizes the need to extensively benchmark scRNA-seq analysis pipelines.  
There are also different cell type deconvolution algorithms, each with different strengths and limitations 
(Li et al. 2017; Qiao et al. 2012; Racle et al. 2017; Finotello et al. 2019). In this work, we selected 
CIBERSORT for its extensive validation on deconvolution of immune subsets, particularly in the 
context of tumour content (Finotello and Trajanoski 2018). However, the accuracy of this tool may be 
affected by not taking into account cross-subject heterogeneity in cell type-specific gene expression as 
well as within-cell type stochasticity of single-cell gene expression (Wang et al. 2019). In addition, the 
expression of single cells can be different between their physiological context (i.e., in a tissue) and when 
they are extracted for sequencing. 
The results obtained and validated in independent datasets clearly state that there is a need to increase 
the biological variability of individuals in single-cell data. Moreover, all of the derived signatures were 
from a specific brain region. Given the potential of scRNA-seq data analyses to go deeper in the 
knowledge of specific cell types and states, cell type deconvolution analyses should be performed using 
the same tissue, in order to discard potential tissue-site bias in the signature.  
Another caveat in our analysis was related with the limited number of samples of patients from young 
age-ranges, particularly in the GTEx dataset, given that we were working with post-mortem healthy 
brain tissue. To validate our results, in the future, we will need to integrate different datasets in order to 
obtain a more comprehensive set of brain tissue samples, equally distributed from young adulthood to 
old age. 
 
8.2. Future perspectives 
 
The remarkable heterogeneity of tumour-infiltrating myeloid cells may conceal the real extent of anti-
tumour effectors and the molecular determinants that control their functions (Kiss et al. 2018). Thus, in 
order to further consolidate our work, we propose to overcome this limitation by bringing individual 
myeloid cell type and state characterization enabled by comparing single-cell transcriptomes. 
Karine Serre’s team at iMM has established a mouse model of tumour regression strictly dependent on 
the presence of myeloid cells, especially macrophages. This is based on the myeloid cell properties to 
respond to stimulatory agents. To further evaluate the cellular diversity and molecular signature of 
myeloid cells with anti-tumour functions, we will generate a scRNA-seq dataset consisting of a mouse 
syngeneic TNBC cell line model injected in the mammary fat pad of mice. We will sort samples of 
tumours with infiltrating anti-tumour myeloid cells (inducing tumour regression) and pro-tumour 
myeloid cells (promoting tumour growth), with particular interest to experimentally-induced 
macrophages with anti-tumour functions. This will be performed using FACS with a myeloid cell bulk 
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marker coupled with the 10X Genomics microdroplet technology. After sorting, single cells will be 
sequenced using an Illumina platform in order to obtain their gene expression profiles. 
This dataset will enable us to further characterise subtypes of infiltrating myeloid cells and define their 
molecular distinctiveness, contributing to the creation of a single-cell expression atlas of myeloid 
lineage-specific anti-tumour molecular effectors. One of the strengths of our project is that we built it at 
the interface between human tumour immunity, evaluated through publicly available transcriptome 
datasets, and the analysis of mouse myeloid cells performing anti-tumour function in breast cancer. This 
way we can determine regulators (effector molecules or transcription factors) of anti-tumour functions 
of myeloid cells from the mouse models and assess their prognostic potential in the human data sets. 
Finally, the characterization of tumour-infiltrating immune cells may disclose better strategies for 
overcoming immune suppression and restoring immunosurveillance in cancer.  
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10. Supplementary figures 
 
 
 
Figure 10.1: Selection of breast tumour bulk RNA-seq samples to perform differential expressional analysis, as described in 
section 6.2.8. Red highlights cut-offs for the proportion of M2 macrophages; Purple highlights cut-offs for the proportion of 
CD8+ T cells.  
 
 
Figure 10.2: t-SNEs of different synthetic scRNA-seq data structures obtained with different clustering methods. Type 1 – 
noisy population; Type 2 - developmental trajectory; Rare - rare cell population. From Tallulah and Hemberg, 2018. 
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Table 10.1: Results from the GO enrichment analysis using marker genes of reactive astrocytes from the Spaethling dataset. 
This analysis was performed using the PANTHER Classification System (Mi et al. 2018) with GO annotations. 
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Table 10.2: Results from the GO enrichment analysis using marker genes of resting astrocytes from the Darmanis dataset. This 
analysis was performed using the PANTHER Classification System (Mi et al. 2018) with GO annotations. 
 
 
